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Abstract 
 
This thesis describes experimental work performed (1998-2001) during the author’s 
involvement with the Brachytherapy group at the Peter MacCallum Cancer Centre 
(PMCC), where he was employed by its Department of Physical Sciences and subsequent 
modeling and analytical studies. When PMCC added HDR brachytherapy to its radiation 
therapy practice, an existing operating suite was considered the ideal location for such 
procedures to be carried out. The integration of brachytherapy into the theatre 
environment was considered logical due to the relatively invasive nature of 
brachytherapy techniques and the availability of medical equipment. This thesis contains 
the detailed study of three key Research Questions involved in clinical aspects relating to 
quality assurance of an HDR brachytherapy practice. An investigative chapter is 
dedicated to the pursuit of each of the Research Questions. 
 
The first question asked… Is the novel approach to using modular shielding combined 
with time and distance constraints adequately optimized during HDR brachytherapy? In 
order to establish optimal clinical practices, this project evaluates the effectiveness of 
additional shielding added to the modular shielding system without modification of the 
previously determined time and distance constraints for PMCC staff, other patients, and 
member of the public. The DOSXYZnrc user code for the EGSnrc Monte Carlo radiation 
transport code has been used to model exposure pathways to strategic locations used for 
measurement in and around the operating theatre suite. Modeling allowed exposure 
pathways to various areas with the facility to be tested without the need to use real 
sources. 
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The second Research Question asked… How well is dose anisotropy characterized in the 
near field range of the clinic’s HDR 
192
Ir source? This study experimentally investigated 
the anisotropy of dose around a 192Ir HDR source in a water phantom using MOSFETs as 
relative dosimeters. In addition, modeling using the DOSRZnrc user code for the EGSnrc 
Monte Carlo radiation transport code was performed to provide a complete dose 
distribution consistent with the MOSFET measurements. Measurements performed for 
radial distances from 5 to 30 mm extend the range of measurements to 5 mm which has 
not been previously reported for this source construction. 
 
The third Research Question is aimed at the patient level… Is the dose delivered to in 
vivo dosimeters, located within critical anatomical structures near the prostate, within 
acceptable clinical tolerance for a large group of HDR prostate patients? An in vivo 
dosimetry technique employing TLDs to experimentally measure doses delivered to the 
urethra and rectum during HDR prostate brachytherapy was investigated. Urethral and 
rectal in vivo measurements for 56 patients have been performed in the initial fraction of 
four-fraction brachytherapy boost. In the absence of comparable in vivo data, the 
following local corrective action level was initially proposed: more than 50% of the 
prostatic urethra receiving a dose 10% beyond the urethral tolerance. The level for 
investigative action is considered from the analyses of dose differences between 
measured data and TPS calculation. 
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Chapter 1 
 
 
Introduction 
 
“Radiation therapy has a long history as a treatment for most forms of cancer, and 
the continuing struggle to control this disease gives constant impetus to efforts to 
refine the various available treatment modalities.” (Subir Nag, 1994). 
 
 
1.1 RADIATION THERAPY PRACTICE 
 
Brachytherapy is grouped with other radiation treatment modalities under the universal 
term Radiation Therapy. Perhaps the best-known technique is External Beam 
Radiotherapy (EBRT), where ionizing radiation is produced in an electron accelerator 
and delivered externally to the patient. Following the introduction of medical electron 
accelerators to Radiation Oncology in the 1960’s, EBRT quickly became the gold 
standard treatment modality due largely to its inherent safety features and tissue sparing 
properties. With relatively little damage to surface tissues, high doses of radiation could 
be delivered to tumours deep within the human body. However, despite certain 
advantages bought to the field there were still limitations, namely the relatively high 
frequency of local relapse and the side effects often associated with a number of body 
sites. Early EBRT practice was constrained by poor delineation of tumour and healthy 
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organ volumes, due largely to the limitations of two-dimensional (2D) imaging devices 
and the use of linear accelerators with minimal beam shaping capabilities. 
 
The last two decades have witnessed attempts to overcome some of these problems 
through the introduction of new technologies and techniques to the field of radiation 
therapy. This has included the employment of innovative ‘3D’ treatment planning 
systems and imaging instruments, as well as external beam shaping devices and new 
standardised definitions for treatment volume identification to more accurately match the 
therapeutically irradiated volume to the irregular tumour volume.  
 
Computerised Tomography (CT) is the gold standard imaging technique in Radiation 
Oncology for delineation of soft tissues that may form part of the visual tumour volume 
or adjacent organs at risk of unwanted exposure. In theory, more accurate tissue 
delineation can lead to a reduction of the dose error margins routinely placed around 
treatment volumes, thereby resulting in the improved shielding of nearby healthy organs. 
This level of image visualisation could also enable superior tailoring of prescribed dose 
volumes in order to minimise undesirable high or low dose regions. Assuming a reduced 
risk of sub-optimal dose coverage, and an increase in effective exclusion of normal 
tissues to large doses, greater dose to the tumour should be clinically tolerable as 
compared to those acceptable with conventional EBRT. 
 
In contrast to external beam irradiation, radioactive material used in brachytherapy is 
customarily introduced into the tumour’s core. When multiple source positions are 
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employed within a therapeutic volume, variation in the surrounding integrated dose 
contours is achieved most easily when positions are organized into parallel, equidistant 
lines. Fine-tuning of implant dose contours to match tumour shapes is achieved by 
varying the line lengths and the time they are positioned. Direct insertion of radioactivity 
into the tumour volume reduces the chance of sub-optimal treatment, resulting from 
geometrical miss or setup errors in day-to-day patient positioning or organ motion. 
 
The distribution of dose delivered from external beam irradiation is regarded as being 
homogeneous, ensuring that the prescribed dose is received throughout the tumour 
volume. For brachytherapy, the corresponding dose distribution is inhomogeneous. In 
fact, the prescribed dose is usually the minimum dose received within the tumour. The 
advantage of brachytherapy, compared to EBRT for the same stated dose, is that regions 
of tumour close to source positions receive a substantially higher dose than the prescribed 
dose. Typically, central regions of an implant receive approximately 50% greater dose 
than that of the periphery. The sharp fall-off in dose from implants provides a further 
advantage of added protection to surrounding normal tissue. Ideally it is possible to 
deliver a much higher dose to the tumour volume than would be clinically acceptable 
with EBRT. With these conditions satisfied, brachytherapy delivers a reasonable mode of 
conformal radiation therapy. 
 
While brachytherapy has the advantage of delivering a tailored dose to small tumours, it 
is usually impractical within the same treatment setup to also give a therapeutic dose to 
the surrounding areas (e.g., adjacent lymph draining areas which may also contain 
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microscopic or gross disease). For specific cases a physician may choose to combine the 
delivery of brachytherapy to a relatively small volume containing the primary tumour, 
while irradiating a wider field with external beam radiation therapy. As less dose is 
required to control surrounding areas that are likely to contain transported tumour cells, 
there is a reduced risk of damage to normal tissue structures that may also be 
encompassed. Brachytherapy dose escalation trials provide treatment outcomes in some 
cases that would be difficult to achieve using any other Oncological therapy. 
 
The current study focuses on several Research Questions about evaluating the 
implementation of high dose rate (HDR) brachytherapy at the Peter MacCallum Cancer 
Centre during the period 1998-2001. The implementation of the brachytherapy program 
in an existing operating theatre without major structural changes may be applicable to 
clinical practice elsewhere. 
 
1. Is the novel approach to using modular shielding combined with time and distance 
constraints adequately optimised during HDR brachytherapy? 
 
2. How well is dose anisotropy characterized in the near field range of the clinic’s 
HDR 192Ir source? 
 
3. Is the dose delivered to in vivo dosimeters, located within critical anatomical 
structures near the prostate, within acceptable clinical tolerance for a large group 
of HDR prostate patients? 
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1.2 HIGH DOSE RATE BRACHTHERAPY: CLINICAL CONSIDERATIONS 
 
1.2.1 Facility options 
 
Setting up an HDR facility requires an investment of capital and human resources. The 
IAEA (TECDOC-1040 &-1257) highlighted three major options for a HDR infrastructure 
in terms of the operational and clinical aspects. They relate to the fundamental work areas 
of a HDR facility including (i) an operating room, (ii) imaging room, (iii) treatment room 
(Figure 1.1), (iv) treatment planning area, (v) console room, and (vi) recovery room. The 
relative proximity of these facilities can significantly influence procedure flow and 
efficiency. Three major options for the first three of these items, in order of increasing 
capital cost, are: 
 
(a) Treatment room for the HDR unit, and shared use of existing operating or 
procedure rooms and imaging systems, such as a CT. The patient transport 
(between operating room, imaging room and treatment room) reduces efficiency 
and hinders immobilization of the implant system 
 
(b) A treatment room for both needle insertion and treatment delivery with imaging 
performed elsewhere. As above, the patient transport reduces efficiency and 
hinders immobilization of the needle system. 
 
(c) Integrated brachytherapy suite. This option adds a dedicated imaging system in 
the treatment room to approach (b). This option is the most efficient requiring no 
transport of the patient between the different steps. 
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Figure 1.1 Depicts floor plan of a conventionally shielded treatment and control 
room, generally, a concrete wall equivalent to 4 cm of lead (i.e., 35 cm thick) is 
recommended. However, the precise thickness and protection approach will depend 
on the room design, the workload, and the local regulations (IAEA 2001). 
Afterloader 
Unit Treatment 
Table 
Treatment 
Console 
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Ideally treatment should be performed in a dedicated brachytherapy suite where needle 
placement, radiographic generation, and treatment can go ahead without the need to shift 
the patient. In terms of medical safety and image localisation issues it is generally 
preferable to minimise movement of the patient. Table 1.1 illustrates the patient transport 
requirements associated with each of IAEA options listed above. 
 
Procedures Option (a) 
1. shared procedure 
room 
2. shared imaging 
room 
3. treatment room 
Option (b) 
1. treatment room 
2. shared imaging 
room 
Option (c) 
1. integrated suite 
Anaesthesia Procedure room Treatment room Integrated suite 
Needle insertion Procedure room Treatment room Integrated suite 
Imaging Imaging room Imaging room Integrated suite 
Treatment Treatment room Treatment room Integrated suite 
Removal of 
applicators 
Treatment room or 
Procedure room 
Treatment room Integrated suite 
 
Table 1.1 illustrates the patient transport requirements associated with each of IAEA 
options (IAEA 2001). 
 
1.2.2 Source and remote afterloading 
 
The first remote afterloading machine to be described in the literature was designed in 
1962 by Rune Walstam, and utilised four 226Ra tubes that were linked in a linear 
arrangement (Mould et al., 1994). The pioneering study by Henschke et al. (1964) from 
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Memorial Sloan-Kettering Cancer Centre, reported on the replacement of 226Ra with high 
activity 60Co sources for the treatment of cervical cancer. The early studies (Henschke et 
al. (1964), O’Connell et al. (1965), Walstam (1965) and Wakabayashi et al. (1971)) 
involved a simple intracavity application, whereby hollow applicators were inserted into 
the vaginal cavity and subsequently loaded remotely with 60Co sources; still an important 
principle of modern techniques in Brachytherapy. The machine-controlled device used 
for source placement, is coined a ‘remote afterloader’ and was first conceived by Sievert 
in 1937 (IAEA 2001). The term ‘Afterloading’ refers to the method by which empty 
catheters or needles are placed in the tissues or in a body cavity and then source is simply 
loaded afterward via remote control. Afterloading offers the advantage that time and care 
may be taken during the implant procedure without staff receiving any radiation 
exposure. 
 
The medical community’s enthusiasm for the new concept was rapid. In 1965 a German 
company introduced an instrument named the ‘GammaMed’, a remote afterloading 
device that used a cyclotron produced 192Ir source (Mundinger and Sauerwein 1966). 
Low dose rate (LDR), medium dose rate (MDR), or high dose rate (HDR) sources can be 
used to perform afterloading brachytherapy. The ICRU report No. 38 (1985) categorized 
the dose rate as follows for LDR, MDR and HDR as 0.4 to 2.0, 2.0 to 12.0 and > 12.0 Gy 
per hour, respectively. Largely due to its low average gamma ray energy and smaller size 
relative to other suitable brachytherapy sources (e.g. 60Co and 137Cs) 192Ir has become the 
favoured high activity radionuclide deployed by modern remote afterloading machines.  
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Typically, modern brachytherapy 192Ir sources are cylindrical (nominal activity of 370 
GBq) with surrounding encapsulation usually stainless steel or titanium. The HDR 192Ir 
source employed for this study was designed by Nucletron-Oldelft International B.V. and 
manufactured by Mallinckrodt Diagnostica (part No. 080950). This source as been coined 
the ‘classic’ design due to the release of a newer source design (Daskalov et al 1998). 
Figure 1.2 illustrates the four major components responsible for attenuation and 
scattering of photons by the Nucletron HDR ‘classic’ 192Ir source; these include the 
stainless steel drive cable (black), plug (grey), encapsulation (blue) and the 192Ir pellet 
(yellow). 
 
Figure 1.2 A schematic diagram of the Nucletron ‘classic’ 192Ir HDR source. 
 
The single source, welded to the end of a drive cable, is controlled and monitored during 
treatment by a microprocessor when travelling between the safe and dwell positions. The 
deposition of energy by the small source tailored by altering the time spent at a various 
locations. In this way simulation of any source configuration or simply a source of a 
longer active length may be achieved. HDR brachytherapy has the added advantage that 
the treatments can be performed in only a few minutes, typically the dose rate employed 
Ir Pellet192
3.5mm
0.4mm
1.1mm
0.6mm
5mm
Drive cable 
Encapsulation 
Plug 
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in current HDR units is about 100-300 Gy per hour (IAEA 2001). 
1.2.3 Verification of source Anisotropy 
 
Besides controlling the irradiating source, modern remote afterloading devices rely on 
computer technologies for the purpose of treatment planning and dosimetry calculations. 
The accuracy of dose calculations for brachytherapy applications is dependant on the 
accuracy of the dosimetric data for sources used. Of particular importance to the present 
study is the verification of source anisotropy as defined in TG-43 (Nath et al.1995). The 
anisotropy function provides a two-dimensional description of the expected angular 
variation of dose rate surrounding the source due to self-filtration (within its cylinder of 
radioactivity), oblique filtration of primary photons through the encapsulating material, 
and scattering of photons in these media. Thus, an anisotropic distribution of dose 
becomes detectable due to a reduction in dose rate relative to a normalised value (i.e., 
°= 90θ ), though positional uncertainties may compromise its measurement. 
 
Before dose can be absorbed within the active volume of a dosimeter (e.g. TLD or 
MOSFET dosimeter) and recorded, photons, either primary and/or scattered, must pass 
through the adjacent material, its encapsulation and surrounding media. The choice of 
media is based first and foremost on physical properties that must closely approximate 
the radiation absorption and scattering properties of soft tissue and muscle. The media for 
routine dosimetry investigation of brachytherapy sources include water, or an established 
tissue substitute material such as Solid Water (ICRU, 1992). 
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A cylindrical source may display a variation in the anisotropy distribution of perhaps 
50%, largely dependant on the type of the radionuclide and source design in question. 
Variation in anisotropy associated with different source design relates primarily to the 
filtration of photons within the structure, and the two principle reasons are: 
 
i. The effect of γ–ray absorption and scattering within the source’s various materials. 
 
ii. The effect of encapsulating material with respect to the source’s transverse axis; 
 
Properties that influence the first mechanism include source dimensions (length relative 
to width), the high-Z construction, and the particular spectrum of emitted photons which 
typically range in energy from 30 keV up to ~ 1 MeV. 
 
In Figure 1.3, Monte Carlo generated results predict a decreased number of primary 
photons and also the corresponding change in energy spectra for photons emitted at 1.0 
cm from an 192Ir HDR source (Karaiskos et al 1998). Predictably the highest probability 
of filtration is associated with those primary photons travelling along the length of the 
source (i.e., °= 0θ ). 
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Figure 1.3 Monte Carlo generated photon spectra at the radial distance of 1.0 cm at 
polar angles of °= 0θ and °90 , relative to the long axis of the Nucletron ‘classic’ 
192Ir HDR source (Karaiskos et al 1998). 
 
The second mechanism, relates to high-Z material, such as stainless steel, in the form of a 
drive cable that is commonly used in commercial HDR brachytherapy afterloading 
devices. Monte Carlo simulation reveals that the thin layer of source encapsulation 
material has negligible impact on the angular dependence of emitted radiation (Meli et al 
1988). However, when a stainless steel drive cable is welded to one end of the source, 
further oblique filtration of primary photons results in an asymmetric dose distribution 
about its transverse axis. 
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1.2.4 Human communication and Equipment function 
 
Clear and concise human communication is a prerequisite of a successful Brachytherapy 
unit. In brachytherapy a number of personnel are required to work closely, each often 
playing a key role in the treatment planning and delivery process, rarely are steps 
performed by one team member acting alone. Table 1.2 lists examples of work areas and 
the interplay of communication between the necessary disciplines on which 
brachytherapy is dependent. 
 
 
Content of communication 
 
From 
 
To 
 
Prescription for treatment 
 
Radiation oncologist 
 
All staff involved in 
planning and delivering 
treatment 
 
Input data for preparation of 
treatment plan 
 
X-ray radiographer 
 
Radiation therapist, 
Physicist 
 
Proposed treatment plan and 
calculation, prescribed dose 
 
Radiation therapist 
 
Medical physicist 
 
Proposed treatment plan and 
confirmed calculation 
 
Medical physicist 
 
Radiation oncologist 
 
Patient immobilisation 
 
Radiation oncologist 
 
Radiation therapist 
 
Confirmed plan 
 
Radiation oncologist 
 
Medical physicist, 
Radiation therapist 
 
Equipment fault report 
 
Radiation therapist 
 
Medical physicist 
 
Request form maintenance 
 
Medical physicist 
 
Engineer 
 
Instruction to discontinue 
treatment 
 
Medical physicist 
 
Radiation oncologist, 
Radiation therapist 
 
Maintenance complete 
 
Engineer 
 
Medical physicist 
 
Check equipment and verify 
that it is ready for use 
 
Medical physicist 
 
Radiation therapist 
 
Table 1.2 Examples of work areas and the interplay of communication between the 
disciplines to which safe brachytherapy practice is dependent on (IAEA 2000). 
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The condition most likely to threaten the well being of the patient is human error, either 
in the characterization of physical source data or in the evaluation and execution of the 
actually brachytherapy procedure. A number of accidents have been reported in both 
LDR and HDR brachytherapy treatment, mainly resulting in an incorrect dose to the 
patient (Table 1.3). An account by type and frequency for accidents reported to the IAEA 
in Brachytherapy treatments were recently published (IAEA 2002). 
 
Accident caused by Number of cases 
Dose calculation error 6 
Error in quantities and units 2 
Incorrect source strength 7 
Equipment Failure 4 
Other (Human mistakes, bad implant, etc…) 13 
Total 32 
 
Table 1.3 Type and frequency for accidents reported to the IAEA in Brachytherapy 
treatments (IAEA 2002). 
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1.3 OVERVIEW OF THESIS 
 
The complexity and integrated nature of HDR brachytherapy incorporates a number of 
disciplines, including Physics, Radiation Oncology, Radiation Therapy, Engineering and 
Nursing, and means that an all-encompassing approach to quality assurance is beyond the 
scope of a single PhD thesis. In this study, work was performed in the clinical setting of 
the operating theatre environment of the PMCC and the three unique questions arose 
directly from the physical needs of the clinic. The investigative projects of this thesis, 
Chapters 3, 4, and 5, each focus on a key question, and address problems at the planning, 
in vivo patient dosimetry, and radiation protection levels of the brachytherapy practice. 
 
Chapter 1 provides the reader with the necessary introductory backdrop which includes 
HDR brachytherapy treatment justification, facility setup options, 192Ir HDR source 
properties, and the multi-disciplinary nature of Brachytherapy practice. Chapter 2 
provides a brief review of radiation protection principles and recommendations that form 
the basis of the rules and regulations that guide this work. This review includes 
optimisation philosophy pertaining to radiation exposure. Chapter 2 also includes a 
review on the importance of in vivo dosimetry for independent monitoring of doses to 
patients and action levels relevant in Chapter 5. 
 
Chapter 3 evaluates the effectiveness of an additional shielding to a novel modular 
shielding system to ensure radiation protection for staff, other patients and the general 
public. PMCC provides reasonable access to the public, whose exposure is more difficult 
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to control, e.g. hospital cafeteria, than in the brachytherapy facility to which the general 
public does not have access. The dose rate at survey meter measurement points around 
the HDR treatment room are calculated using the DOSXYZnrc user code of the EGSnrc 
Monte Carlo radiation transport and simulation code. The Monte Carlo simulations rely 
on a good knowledge of the structural components that form the barriers to radiation, 
architectural drawings alone may not provide this. The discrepancies between 
measurement and Monte Carlo modeling are analysed with a view to estimate unknown 
barrier thickness and hence provide the reader with information useful for application in 
other centres. 
 
Chapter 4 evaluates the feasibility of using MOSFET dosimeters to measure dose 
anisotropy for the Nucletron ‘classic’ 192Ir HDR source. Using a motorized source-
dosimeter arrangement in a water phantom, and software for efficient collection of data, 
experiments are performed for radial distances from 5 to 30 mm. The MOSFET results 
are compared to a model of the experimental arrangement using the DOSRZnrc user code 
for the EGSnrc radiation transport and simulation code. The anisotropy data and model 
are benchmarked against published Monte Carlo simulations of the dose distribution as 
well as measurements using TLDs where they exist. 
 
Chapter 5 describes an independent evaluation of dose using in vivo dosimetry on the 
initial fraction of a four-fraction HDR brachytherapy boost treatment for a large group of 
patients with localized prostate cancer. The comparisons are performed in the current 
study between experimental data collected by a TLD train within the urethra and rectum, 
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and TPS calculations. Monte Carlo simulation is used to study TLD volume-averaging 
effects and the influence of radiopaque brass spacers separating the TLDs on the 
measured dose. A proposed corrective action level for the urethra is evaluated for 54 
patients with a view to provide recommendations for an investigative action level. 
 
An HDR brachytherapy program utilising state-of-the-equipment offers the prospects of 
improved clinical outcome, if and only if, such technologies are implemented correctly 
with appropriate quality assurance. Chapter 6 presents a general discussion on the 
conclusions drawn during the course of the study, elements of which may be useful to 
HDR brachytherapy programs planned elsewhere in the future. 
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24(4): 2001. 
 
2. Toye W.C., Das K.R., Todd S.P., Kenny M. and Johnston P.N. Automated 
brachytherapy dosimetry system. Radiother. Oncol. 55 Supl:58: 105, 2000. 
 
3. Toye W.C., Das K.R., Kilby W.D., Mameghan H. and Duchesne G.M. Routine 
confirmation of urethral and rectal doses for prostate high dose rate brachytherapy 
with in vivo measurement, Radiother. Oncol. 55 Sup1, 88: 171, 2000. 
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For the convenience of the examiners, reprints of these publications are included in 
Appendix B.
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Chapter 2 
 
 
Review of Relevant Radiation Protection Principles 
 
2.1 INTRODUCTION 
 
Once a treatment application using HDR brachytherapy has been justified and adopted, it 
is necessary to consider how best to use resources in reducing further the radiation 
exposure to workers, patients, and the public (ICRP 1990). The broad aim being to ensure 
that the magnitude of the individual doses, the number of people exposed, and the 
likelihood of incurring exposures where these are not certain to be received, are all kept 
as low as reasonably achievable (ALARA), economic and social factors being taken into 
account (ICRP 1990). The ALARA plan for radiation protection can be further optimised 
by following steps in the procedure shown in Figure 2.1 (IAEA 2002). 
 
The output of an optimization study will be an ALARA plan with both short and longer 
term objectives known as ALARA goals (IAEA 2002). For an HDR brachytherapy 
facility identification of goals that highlight the main areas for improvement must be 
considered for each category of exposure whether occupational, public or medical. These 
goals might include patient in vivo dose targets, maximum individual doses and collective 
dose targets, as well as dose pattern results determined from a shielding survey. The 
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survey results should be evaluated in consideration of the actual operating conditions, 
length of treatment, personnel occupancy, and attenuation by the patient. 
 
 
 
Figure 2.1 The optimization procedure for an ALARA plan recommended by the 
IAEA (2002). 
 
2.2 THE CLASSIFICATION OF WORK AREAS 
 
A common-sense approach to exercising control of the source of exposure and over the 
workers who are occupationally exposed has been recommended by the ICRP (1990). It 
involves formally designated proximal localities to the source into controlled and 
 
Identification and quantification of dose 
reduction factors 
 
Recommended options for protection 
Decision as a basis for an ALARA plan and its 
implementation 
Implementation 
and 
feedback 
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supervised areas (ICRP 1990). A controlled area is one in which access may restricted 
during periods of irradiation, requiring workers to follow well-established procedures and 
practices aimed specifically at strictly controlling radiation exposures. In identifying a 
controlled area, it may be useful to make use of existing physical boundaries, such as the 
external walls of the facility and/or room walls (IAEA 1999). A supervised area shall be 
designated in any area not already designated as a controlled area, but where occupational 
exposure conditions need to be kept under review even though specific protection 
measures and safety provisions are not normally needed (BSS 1996). 
 
The ICRP recommend that the classification of work areas are best based on operational 
experience and judgement, taking into account both expected exposure levels and of the 
likely variations in these exposures. Designation of areas may be defined in terms of the 
dose rate at the boundary, with the aim of ensuring that anyone outside a designated are 
will not need to be regarded as occupationally exposed (ICRP 1990). Thus, doses 
received outside the designated areas should be low enough to ensure that in normal 
conditions, the level of protection for those who work in the facility will be less than the 
dose constraint of 1 mSv per year (ICRP 1996). Values of dose rate based on a fraction of 
the relevant dose limit have often been used in the past for defining the boundaries of 
controlled areas (IAEA 1999). However, careful consideration should be taken of the 
length of time for which the dose rate remains at or above the defined level and the risk 
from potential exposures. Periodic review of the exposure situation will highlight the 
need for extra protective measures or changes to the boundary of a work area. 
 
 26
In the case of remote afterloading brachytherapy, the use of periodic irradiation calls for 
some flexibility of temporary designation of controlled and supervised areas. Signs at 
entrances to controlled area should be used to indicate to staff, especially to maintenance 
staff, the special procedures currently apply in the area and that a radiation source is 
likely to be present (ICRP 1996). 
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2.3 OCCUPANCY FACTORS 
 
Evaluation of strategically shielded HDR facility must certainly involve an estimation of 
occupancy for all adjacent areas. The occupancy factor for each selected monitoring site 
should represent the average time that the maximally exposed individual is present when 
the radiation is present (NCRP 2004). Thus, for a HDR afterloader that is used randomly 
during working hours each week, the occupancy factor will be a fraction of the working 
hours in a week, averaged over the year. NCRP No 147 (2004) provides a list of 
suggested occupancy factors that are to be used as a guide in calculations when accurate 
occupancy data are not available (Table 2.1). 
 
 
Location 
 
Occupancy 
Factor (T) 
 
 
Administrative or clerical offices; laboratories, pharmacies and other 
work area fully occupied by an individual; receptionist areas, 
attended waiting room, nurse’s stations, radiation control rooms 
 
1 
 
Corridors, patient rooms, employee lounges, staff rest rooms 
 
1/5 
 
Corridors doors 
 
1/8 
 
Public toilets, storage rooms, outdoor areas with seating, unattended 
waiting room, patient holding areas 
 
1/20 
 
Outdoor areas with only transient pedestrian or vehicular traffic, 
unattended parking lots, stairways, unattended elevators, janitor’s 
closets. 
 
1/40 
  
 
Table 2.1 Suggested occupancy factors extracted form NCRP 147 Table 4.1 (2004). 
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2.4 ASSESSMENT OF OCCUPATIONAL EXPOSURE 
 
During the implementation or evaluation of a radiation protection plan there should be 
tracking of changes to plan outcome indicators enabling the opportunity for feedback 
(Figure 2.1). This routinely occurs for occupational exposure in the form of individual 
monitoring or in the form of a radiation surveying. 
 
In the characterization of occupation exposure, the main indicators to be examined are the 
level of the collective dose and the distribution of individual doses (IAEA 2002). The 
assessment of collective dose from occupation exposure is usually based on the recorded 
dose from individual monitoring. Such information provides confidence and may provide 
data of use in reviewing the radiation protection program. Workers exposed to radiation 
from sources not related to, or required by their work shall receive the same level of 
protection as if they were members of the public (BSS 1996). A formal individual dose 
assessment would normally be performed should monitoring indicate that the 
corresponding annual effective dose exceeds 1 mSv, and should certainly be conducted 
for total annual effective doses estimated to be above 5 mSv (IAEA 1999). 
 
In the case of shielding design, goals are used in the evaluation of the effectiveness of 
barrier construction for the required level of protection. Ideally one should perform a 
radiation survey when the HDR source is of greatest activity, sampling nearby controlled 
and uncontrolled areas. In addition to providing information on the control of 
occupational exposure, a program of individual monitoring may be helpful in confirming 
the classification of work areas. For example, when combined with data on the frequency 
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of the jobs performed, their duration, measured dose rates and the number of workers 
exposed. In practice, it is possible to achieve an accuracy of about 10% at the 95% 
confidence level for measurements of radiation fields in good laboratory conditions 
(ICRP 1990). The NCRP recommend the setting of a weekly shielding design goal for a 
controlled area at an equivalent dose value of 0.1 mSv per week and 0.02 mSv per week 
for an uncontrolled area. 
 
Measurements should be made at a number of occupied distances from the source, 
including outside the facility (e.g. on the roof or an adjacent footpath). The measurements 
should be taken from the source to the nearest likely approach of the sensitive organs of a 
person to the barrier (NRCP 2004). The NCRP recommend a measurement point of no 
closer than 30 cm to a wall. For the floor below, not higher than 1.7 m from that floor 
level and, for ceiling transmission, a distance of at least 0.5 m above the floor of the room 
above (NRCP 2004). If, as a result of a radiation survey, supplementary shielding is 
added to the protective barriers, the survey should be repeated to evaluate the adequacy 
of the shielding after the modification. 
 
2.5 ASSESSMENT OF MEDICAL DOSE 
 
Independent in vivo monitoring of medically exposed patients is much less common. The 
in vivo measured doses may then be helpful in verifying a reference level that may be 
used as a trigger above which some specified remedial action or decision should be taken 
(BSS 1996). 
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The employment of detectors with high spatial resolution by means of an in vivo 
technique is a practical approach for verifying accuracy of brachytherapy practice for an 
individual patient. Particular interest relates to the monitoring of dose deposited in 
adjacent normal tissue caught unavoidably in the path of ionizing radiation where small-
unintended increases in irradiation can cause injury of varying severity e.g., to the rectum 
or to the urethra during treatment of the prostate. While biological effects of ionizing 
radiation are not known with complete certainty, the physical parameter of radiation, dose 
(energy absorbed per unit mass of tissue), is well defined and is used as an established 
criterion of biological effect (ICRU 1985). 
 
A report by the American Association of Physicists in Medicine (AAPM) Radiation 
Therapy Committee Task Group 40 (TG-40), on comprehensive QA for radiation 
oncology, recommend all patient dose calculations should be reviewed by verification 
that no gross errors have occurred (Kutcher et al. 1994). They recommend that this be 
done in a timely fashion so errors can be corrected before treatment is complete. TG-40 
recommends agreement should be within 15% (possible larger for multi-plane interstitial 
LDR implants) between the independent checks and dose calculation. A recent report 
AAPM TG-56 on the code of practice for brachytherapy physics, recommended that 
measurements with TLD or diode detectors are likely to yield an associated uncertainty 
of more than ± 10% (Nath et al. 1997). 
 
 31
The IAEA Safety Reports Series No. 17 – Lessons learned from accidental exposures in 
radiotherapy (IAEA 2000) comments that  
“…there is no single sharp limit for the deviation on which the decision that a 
deviation is ‘substantial’ enough to constitute an accidental exposure from the 
point of view of the outcome can be based; nevertheless, for practical reasons, 
the generic level of 20% has been chosen by some National authorities to make 
an investigation mandatory (10% if the prescribed number of fractions is equal 
to or less than 3).” 
 
The United Sates National Regulatory Commission (USNRC) regulations 10 CFR 35 
stipulate that a medical event be reported if the total dose delivered differs from the 
prescribed dose by 20% or more, or when the fractionated dose delivered differs from the 
prescribed dose, for a single fraction, by 50% or more. After finding that a particular QA 
test reveals an acceptably low incidence of errors, a recommendation could be made for 
dropping the test or increasing the action level. 
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Chapter 3 
 
Optimisation of Local Shielding Design  
for HDR Brachytherapy in a 
Functioning Operating Suite 
 
In this chapter a novel modular shielding system (Sephton et al. 1999) implemented at 
the Peter MacCallum Cancer Centre (PMCC) was evaluated for the purpose of enabling 
an operating theatre suite to serve as a HDR brachytheapy treatment room while surgical 
procedures may be in progress in any one of the other three operating theatres. The 
effectiveness of additional shielding is considered without modification of the previously 
determined time and distance constraints for PMCC staff and members of the public. The 
dose rate at a number of key locations around the HDR treatment room are estimated 
using a comprehensive Monte Carlo radiation transport simulation. This work is 
significant as little Monte Carlo simulation has been published that evaluates dose in 
areas with high scatter contributions. Previous studies have focused on attenuation based 
calculations that relate to determining shielding thicknesses. This deficiency of 
evaluation publications has also been observed by Perez-Calatayud et al. 2004. In the 
current study, Monte Carlo calculated dose rates are compared to measured data and to 
the pre-installation empirical calculations. 
 
Detailed Monte Carlo modeling enabled dose rates to be estimated for scenarios which 
are not easily measured, or are impractical to measure in day-to-day practice in an 
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operating theatre environment. For example, the absolute influence of an individual 
shielding component can only be measured by repeating a survey with the component 
removed. This cannot be done with an exposed source in a clinical setting. The need to 
evaluate room components may arise when considering new equipment purchase options, 
such as a different type of operating table that may lie within an evaluated exposure 
pathway. The model also allows retrospective assessment of measurement points to 
ensure the best locations are chosen for future optimization evaluations. Discrepancies 
between measured and modeled data are considered in terms of unknown parameters in 
structural details and how these may influence conclusions drawn upon measured or 
empirically determined values. The Monte Carlo simulation is an extremely useful tool 
for this type of assessment and may be used to fill gaps in the measurable data. The 
provision of more realistic dose calculations, in contrast to conservative dose upper 
bounds arrived at using a radiation protection approach, can result in measurable cost 
reductions (Facure and Silva 2007). 
 
3.1 BACKGROUND 
 
A novel approach to radiation protection using modular shielding combined with time 
and distance constraints was designed to allow HDR brachytherapy within an operating 
theatre suite at the Peter MacCallum Cancer Centre. The results of this work, published 
by Sephton et al. in 1999, were cited in a recent AAPM publication ‘Brachytherapy 
Physics Second, Chapter 10 ‘Brachytherapy Facility Design’ Glasgow et al (2006) 
referring readers to the work as an example of the effective use of local shielding for 
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HDR in operating rooms (ORs). The initial shielding design was based on pre-installation 
empirical calculations performed in 1996, and the arrangement tested with a decayed 
source (the results of which were presented in 1997 at the ACPSEM conference ‘PERM-
IT ’97’ by the candidate). The published work culminated in 1998 with the experimental 
evaluation of a revised arrangement with a 370 GBq 192Ir source. The candidate’s 
scientific involvement in the work commenced with the experimental evaluation of the 
revised shielding arrangement, the results of which were published (Sephton et al. 1999). 
It was reported that the general concept of portable shielding was working well and 
recommended that a similar approach could be adopted in OR’s elsewhere where more 
conventional forms of radiation protection may not be feasible. 
 
A detailed evaluation of the shielding design, including Monte Carlo radiation transport 
modeling as recommended by Perez-Calatayud et al. (2004), enables the contribution of 
each component of the system to be assessed. This can assist other investigators 
considering adopting some or all of the features of the shielding design and possible 
variations to suit particular clinical configurations. Monte Carlo modeling allows dose 
due to scattered radiation to be incorporated more effectively into calculations and 
provides an efficient method of evaluating potential changes to scatter inducing 
components within the HDR facility. 
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3.1.1 Components to the PMCC shielding design 
 
Theatre four was chosen to serve as the HDR facility as it is sufficiently isolated from other 
theatre staff and patients and the general public during periods of treatment (Figure 3.1). 
Figure 3.1 depicts the shielded room the normal location of the treatment table and HDR 
afterloader unit. The position of the bed can be changed only marginally (floor marked) 
due to the location of the unit connections cabling through the wall (Sephton et al. 1997). 
 
The modular shielding consists of under table shielding inserted within the table cassette 
holder in four pieces for ease of handling (Figure 3.2), and mobile shields positioned in 
close proximity to one side of the HDR treatment table (Figure 3.3). The wooden theatre 
doors were lined with 3 mm of lead. A critical component of the protection design was 
the use of mobile shielding in close proximity to the treatment table. The protection 
analyses related to a 3 shield arrangement with one shield positioned parallel to the long 
axis of the table with the end shields overlapping this shield at an angle of approximately 
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45°.As a result of the evaluation the shielding design was optimized with the addition of 
a fourth mobile shield that overlapped the single shield parallel to the long axis of the 
table (Figure 3.3), while an additional channel shield (Figure 3.4) provided extra 
attenuation for the cafeteria below during source transit to and from the PTV (Sephton et 
al. 1999). 
 
Figure 3.2a The under table shielding consists of two pairs of individual lead 
panels for easy handling, The length of one pair was a little less than the other. 
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 Figure 3.2b The under-table shielding was positioned in two layers. Using a 
combination of different width shields the joins in each layer (400 x 450 mm2) were 
offset. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3a The revised arrangement of the mobile shields is shown, with the extra 
mobile shield positioned at the side of the operating table. The overlapped shield edges 
results in a reduction of exposure to the theatre setup area. Shown are a number of Survey 
points from 1 to 12. 
 
Figure 3.3b Firstly, the two side shields (750 x 800 mm2) are positioned 
overlapping to the red mark, the remaining shields (750 x 1000 mm2) are then 
  
  
Mobile Lead Shields
  
Theatre
 
Set-Up
  
 
  
(HDR BT)
 Theatre 4
  
HDR
  
Control
 
Room
 
Theatre
 
Store
  
Room
  
Chain 4
 
Red mark 
External Wall 
1 
7 
12 
10 
2 
CSSD 
 
8 
Chain 3 Chain 2 
An Extra mobile shield 
overlaps the existing 
shield 
 
 39
overlapped at each end. The bed height was adjusted so that the source position 
within the patient during treatment approximated the mid-height of the shields 
 
Figure 3.4 A 500 mm length channel of semi circular cross section and 8 mm Pb 
thickness 
 
The implementation of a local shielding design must suit a HDR clinic’s requirements for 
patient treatment with minimal interruptions to the workflow of other procedures close by 
within the operating suite. At the PMCC site, necessary requirements of the HDR facility 
included: 
• That the centre’s workload be accommodated safely. 
• That the facility can safely accommodate an intra-operative setting that relies on 
repositioning the operating table to the centre of the treatment room. 
 
• That appropriate reduction of exposure is achievable with the use of existing 
barriers and modular shielding that must be positioned in a reproducible manner 
for individual procedures. 
 
• That nearby assessable areas by effectively converted to controlled areas to 
reduce exposure during periods of HDR treatment (Figure 3.5). 
 
 40
• That current regulatory dose limits and dose constraints are met. 
 
 
Figure 3.5 Interlocked removable chain barriers defined the boundary of controlled 
areas. If any one of the interlocks is potentially triggered during treatment, the source 
will require 4 s to retract back into the unit. The controlled areas are reverted back to a 
non-controlled status following treatment, only after the physicist has verified the safe 
return of the HDR source to the afterloaders internal lead container. 
 
To help determine whether each of these requirements are met, strategic pathways of 
exposure were evaluated both inside and outside the operating suite to establish those 
most at risk during a brachytherapy treatment. 
 
3.1.2 Key exposure pathways in and around the operating theatre suite 
 
The theatre suite is of an older construction with higher ceilings and thicker barriers than 
a more modern construction. The exposure pathways identified as being of particular 
importance from a radiation protection by standpoint include: the HDR control room; 
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theatre 1 setup area and operating room; a pathway to the CSSD entrance; a pathway to 
chain 2; roof area directly above; a street footpath; verandah and cafeteria below. 
Survey Point 1 is located in front of the HDR control console where the operator is to 
stand at commencement of patient treatment (Figure 3.6). At 8 m from the source the 2 
cm mobile lead shielding and two internal brick walls each 10 cm in thickness attenuate 
the 192Ir photons. 
Survey Point 2 is located just outside the treatment room doors. The 192Ir photons are 
attenuated by 20 mm of lead shielding and solid wooden doors lined with 3 mm of lead 
(Figure 3.6). 
Survey Point 3 is located waist height on the roof 4 m above the treatment area (Figure 
3.6). The 192Ir photons are attenuated by a 20 cm concrete slab as well as ceiling material 
and tiles. 
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Figure 3.6 Cross section of treatment area and area directly above. Diagram shows the 
source position relative to nearby material barriers such as lead shielding within the 
operating table, mobile lead shielding. Survey points 1 to 3 and 11 are shown. 
 
Survey Point 4 is located at waist height above the footpath 8 m obliquely from the 192Ir 
source (Figure 3.7). The beam is attenuated by 16 mm of under table shielding and by the 
base of the operating table. 
Survey Point 5 located at the verandah is attenuated by 16 mm of lead shielding, base of 
table and the concrete floor. It sits a distance of 4 m from the source (Figure 3.7). 
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Figure 3.7 Cross section of treatment room area, floor and footpath below. Survey 
points 4 to 7 are shown. 
 
Survey Point 6 The nearest section of the cafeteria is located approximately 4 m from 
the source. The beam is attenuated by 16 mm of lead and the base of the operating table 
and concrete floor obliquely (Figure 3.7). 
Survey Point 7 is located in the theatre 1 setup area is 6 m from the 192Ir source. The 
beam is attenuated by 20 mm lead shielding that overlap and a single brick wall 10 cm 
thick (Figure 3.7). 
Survey Point 8, located in the theatre clean-up area, is 11 m from the source. Radiation 
to this point is attenuated by 20 mm thick lead mobile shielding and the 3 mm lead lined 
door (Figure 3.3a). 
Survey Point 9 is at the centre of Theatre 1 the closest of three theatres, the point is 10 m 
from the source (Figure 3.1). 
Survey Point 10 lies 11 m from the source in the Central Sterilising Services 
Department, the radiation to this point is attenuated by the 20 mm lead mobile shielding, 
and scatter from the 3 mm lead lined doors (Figure 3.3a). 
Survey Point 11 lies 9 m from the source in an end room of Ward 2 (Figure 3.6). barriers 
in the path of the 192Ir photons include a 20 cm thick concrete slab (obliquely) and double 
brick exterior wall. 
Survey Point 12 is located 7 m from the source; the radiation to this point is attenuated 
by the 20 mm lead mobile shielding, an internal brick wall and scatter from the 3 mm 
lead lined doors (Figure 3.3a). 
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3.1.3 Empirical calculation 
 
Calculations of the dose rate attenuated by the barriers are determined for each of the 
survey points surrounding the treatment room. The dose rate to each survey point was 
determined by multiplying the 192Ir photon attenuation factors by the workload and 
occupancy, divided by the square of the distance from the source. When the HDR facility 
was intended to complement the existing LDR program, calculations are based on a 
maximum usage of 70 minutes per week or 60 hours per year. 
 
 Material Thickness (cm) Attenuation 
Solid wood 3.0 Doors 
Lead 0.3 
 
1/2 
Table shielding Lead 1.6 1/10 
Mobile shielding Lead 2.0 1/10 
Wall internal Single brick 10 1/4 
Wall external Double brick 20 1/15 
Floor Concrete 20 1/20 
Roof Concrete 20 1/20 
 
Table 3.1. The attenuations for the various shielding barriers 
 
Occupancy factors determined in part from recommendations (Table 2.1) and experience 
were assigned to each area. The temporary controlled area (ICRP 1990) was defined by 
the theatre wall structure, chain barriers (Figure 8) and by closing off entry to an access 
corridor through the sterilizing department and HDR control room (Figure 1). When the 
controlled area was emptied of all theatre staff, essential treatment personnel occupied 
the control room during treatment (Figure 3.1) from which the afterloader may only be 
operated once all interlocks have been set. 
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       Location 
 
Material in Path Distance Dose rate 
µSv/hr 
Occupancy Annual dose 
µSv 
1. Control Room Mobile shielding 
Brick wall x2 
 
7 
 
6 
 
1 
 
360 
2. Theatre doors Lead lined 
Wooden door 
 
6 
 
69 
 
0 
0 
3. Roof Area Concrete roof 
 
 
4 
 
156 
 
0 
 
0 
4. Footpath Table shielding 
Concrete floor 
 
8 
 
4 
 
1/4 
 
60 
5. Staff Cafeteria 
    Verandah 
Table shielding 
Concrete floor 
 
4 
 
16 
 
1 
 
960 
6. Staff Cafeteria 
    In doors 
Table shielding 
Concrete floor 
 
4.5 
 
12 
 
1 
 
720 
7. Theatre setup Mobile shielding 
Brick wall 
 
6 
 
35 
 
1/4 
 
525 
8. Chain 2 Mobile shielding 
Lead lined 
Wooden door 
 
11 
 
21 
 
1 
 
1240 
9. Theatre 1 Mobile shielding 
Brick wall 
 
10 
 
13 
 
1 
 
780 
10. CSSD Mobile shielding 
Lead lined 
Wooden door 
 
11 
 
21 
 
1 
 
1240 
11. Ward 2 
     (oblique) 
Concrete roof 
Double brick wall 
 
8 
 
0.1 
 
1 
 
8 
 
Table 3.2 Empirical Calculations  
 
 
Example empirical calculation: 
  Dose rate at Control room 
  The 370 GBq 192Ir delivers a dose rate of approximately 50 mSv/hr 
  The control room was estimated to be 7m from the source. 
 
   = 50 x 103 x 1/49 x 
1/10 x 
1/4 x 
1/4 
  = 6 µSv/hr 
  = 360 µSv/yr (assuming a 60 hr per year usage) 
10 mm brick wall (Table 
20 mm lead mobile shielding 
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3.1.4 Area Survey Measurements 
 
Measurements were performed on a number of separate occasions with a Victoreen 450P 
ion-chamber monitor with a specified uncertainty in measurements of 10%, according to 
the Operation and Instruction Manual. Measurements in Table 3.3 were performed 
without a patient, but with the HDR 192Ir source positioned similarly to that during a 
treatment. The monitor held 30 cm from a wall and at waist height. For measurements in 
the controlled areas, the monitor was placed on a trolley at an approximately waist height. 
 
Location 
Occupancy 
(%) 
Distance 
(m) 
Material in Path 
Dose-rate 
(µSv/hr) 
Control room 100 7 
20mm Pb 
2 × 100mm brick 
3 
Theatre passage 0 6 
20mm Pb 
door (wood + 3mm Pb) 
30 
Roof 0 4 
200mm concrete 
roof sealing, tiling 
34 
Footpath 25 
8 
(oblique) 
16mm Pb 
200mm concrete 
2 
Cafeteria 100 4 
16mm Pb 
200mm concrete 
base of operating table 
3 
Theatre 1 setup 25 6 
20mm Pb 
100mm brick 
27 
Theatre cleanup 100 11 
20mm Pb 
door (wood + 3mm Pb) 
3 
Theatre 1 100 10 
20mm Pb 
100mm brick 
4 
Sterilising Dept 100 11 
20mm Pb 
door (wood + 3mm Pb) 
3 
 
Table 3.3 Dose-rates measured in areas adjacent to HDR brachytherapy room, with 
all local shielding in place and the 370 GBq source out on the treatment table 
(Sephton et al. 1999). A maximum source usage of 60 hrs per annum is estimated. 
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Sephton et al (1999) measured the effectiveness of individual shielding components. The 
wooden doors, with 3mm Pb added, reduced the dose just outside the entrance by a factor 
~ 6 (Figure 3.6). The mobile 20mm Pb shields reduced dose to the set-up room by a 
factor of 10-15 (Figure 3.7), the composite 16mm Pb shield under the table reduced the 
dose to occupies areas below, by a factor ~8 (Figure 3.7).  
 
3.2 METHODS AND MATERIALS 
 
The exposure pathways within the operating theatre suite and to surrounding areas during 
HDR brachytherapy are modelled using the DOSXYZnrc user code (Walters et al. 2005) 
to evaluate the dose rates at 12 survey points. DOSXYZnrc is well suited to the mostly 
rectilinear construction of the building in which the operating theatre is located on the 
second floor. The EGSnrc system with DOSXYZnrc user code is well established for 
photon beam dose calculations (Kawrakow and Walters 2006). DOSXYZnrc calculates 
dose to water explicitly in the model without the need to model the Victoreen ion-
chamber response, and the subsequent conversion to dose. The detection volumes are 
larger than the ion chamber to improve efficiency and reduce simulation times.  
 
Simulation is unable to account for contributions to exposure rates due to variations in the 
daily setup of the modular shielding design, for example ensuring the under table 
shielding attenuates all dwell positions or that the mobile shielding is sufficiently 
overlapped. For this reason, and also to give the reader a quantitative perspective on the 
impact of the local shielding to exposure pathways a worst case scenario of no shielding 
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has also been modeled. To help evaluate the sensitivity of individual shielding 
components the HDR treatment room was modeled with all modular shielding but in the 
absence of the lead lined theatre doors. To provide a more realistic evaluation of the 
exposure rate routinely experienced at the survey points during treatment Monte Carlo 
simulations with a patient scatter surrounding the source are also modeled. 
 
3.2.1 Preliminary Monte Carlo test with simple site configuration 
 
The Monte Carlo modeling of local shielding was preceded by preliminary modeling of a 
simple HDR suite configuration of the Loyola University Medical Centre Outpatient 
Clinic, as some radiological and structural details are presented by Glasgow in Chapter 
10 of the AAPM Brachytherapy Physics Second edition 2006. The recent publication 
provided an opportunity to test the practicality of the Monte Carlo approach with a site of 
simple configuration from a modeling point of view. The HDR suite located in the 
basement was modeled using the same ordinary concrete composition and density as used 
in the PMCC site (3.2.2) simulation with wall and ceiling thickness of 38 cm and 30.5 cm 
respectively. A single door with a lead thickness of 4.5 cm is the only entrance to the 
room. By way of an occupational dose constraint the text refers to satisfying a 20 µSv/hr 
requirement. 
 
The Loyola Monte Carlo model estimates the dose to a water phantom on the floor above, 
adjacent to the HDR console area located behind the concrete wall (point A in Figure 
3.8), as well as an area adjacent to the lead door. For the floor above the Monte Carlo 
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calculated a value of 24 µSv/hr which is consistent with 14 µSv/hr reported in the text. In 
the Control Area, the average dose rate determined by the current Monte Carlo simulation 
was 27 µSv/hr (see Figure 3.8 for the location of the array of cells sampled for dose) with 
a minimum of 9 µSv/hr adjacent to the control console and a maximum of 56 µSv/hr 
(point B in Figure 3.8) at a location aligned approximately with the centre of the door. 
This is also consistent with the Loyola results as it is reported that “from experience, only 
one patient can be treated in any one hour” (Glasgow 2006). 
 
 
 *Diagram not to scale 
Figure 3.8 Diagram of the Loyola site construction from the dimensions given 
in Chapter 10 of the AAPM Brachytherapy Physics Second edition, Glasgow 
2006. 
 
3.2.2 Monte Carlo modeling of local shielding in the PMCC operating theatre suite 
 
In this study, the source was modeled using the standard routine for uniform isotropically 
radiation parallelpiped source. The simulation utilised the 192Ir spectrum, 
A 
Lead 
192Ir 
Treatment B 
Array of 
Dose 
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‘Ir192_microSelectron.spectrum’ with an average energy of 370 keV (Rogers et al. 2005, 
Borg and Rogers 1999) with global electron cutoff energy ECUT = 0.7MeV and global 
photon cutoff energy PCUT = 0.01 MeV. 
 
The geometry of the operating theatre suite and surrounding areas was modeled such that 
the exposure pathways of interest were constructed from those materials most effective in 
attenuating the 192Ir photons. The roof and floor are represented by a 20 cm concrete slab, 
the internal and external walls are represented by 10 and 20 cm of brick respectively, 
while the theatre doors consist of 3 cm of wood with a 0.3 cm lining of lead. Attenuation 
of photons through the operating table base is modeled with a 1 cm layer of steel. The 
table and mobile shielding are represented by layers of lead 1.6 cm and 2.0 cm thick, 
respectively. Barrier compositions by weight percentage of wood (0.63 gcm-3) 6% H, 
54% C and 40% O (Facure et al. 2006) and for concrete (2.35 gcm-3) 2.2% H, 0.3% C, 
57.5% O, 1.5% Na, 0.1% Mg, 2.0% Al, 30.5% Si, 1.0% K, 43% Ca, 0.6% Fe (NIST). 
 
The photons interacting with the simulated detector allow simulation of dose averaged 
over the detector volume. The dose rate at the detector was predicted by tracking at least 
109 photon histories in each model to achieve a statistical uncertainty in modelled dose 
rate of less than 5% for all detector locations. 
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3.3 RESULTS 
 
The Monte Carlo simulations relating to the local shielding approach are presented in 
Table 3.4 including: full shielding; with and without a phantom scatterer representing a 
patient; and a worst case scenario, that is no shielding and no phantom. 
 
Survey point 
No      location 
Attenuating 
Material 
Distance  No phantom Phantom* 
No shielding 
No phantom 
1.Control Room Mobile shielding 
Brick wall x2 
7 2  64 
2. Theatre Corr. Lead lined 
Wooden door 
6 26  1646 
3. Roof  Concrete roof 4 204 35 204 
4. Footpath Table shielding 
Concrete floor 
8    
5.Staff Cafeteria 
     (Varandah) 
Table shielding 
Concrete floor 
4 10  166 
6.Staff Cafeteria 
    (Indoors) 
Table shielding 
Concrete floor 
4.5 8   
7. Theatre setup Mobile shielding 
Brick wall 
6 42 14 707 
8.Theatre clean. 
Mobile shielding 
Lead lined 
Wooden door 
11 11  470 
9. Theatre 1 Mobile shielding 
Brick wall 
10 10  169 
10. Steril. Dept 
Mobile shielding 
Lead lined 
Wooden door 
11 11  470 
12. Chain 4 
Mobile shielding 
Brick wall 
7 18  958 
*Source positioned in the centre of a 40x40x40 cm3 phantom 
 
Table 3.4 EGSnrc Monte Carlo simulated hourly dose rates 
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The statistical uncertainty in modeled dose rate depends on the percentage of beam 
attenuated and the distance from the source. For survey points with the shielding removed 
the modeling uncertainty was less than 1%. With all shielding modelled, a maximum 
statistical uncertainty of 5% was recorded for the control room.  
 
Table 3.5 Compares the experimental measurements with empirical calculation and 
Monte Carlo modeling of annual dose rate to a representative person. The values at each 
point assume a 60 hour source out time and are corrected for occupancy. The occupancy 
factor is derived from the NCRP philosophy (see Section 2.3) and local experience 
(Sephton et al. 1999). 
 
Annual dose estimates to occupied areas 
Location Empirical Measurement 
Monte 
Carlo 
Control Room 383 180 120 
Footpath 59 30  
Staff Cafeteria* 960 180 600 
Theatre setup 521 405 630 
Theatre cleanup 1240 180 470 
Theatre 1 750 240 570 
Sterilising Dept 1240 180 470 
*Staff Cafeteria represented by dose to the Verandah. 
Table 3.5 Annual dose estimates to occupied areas for 60 hours of usage. 
Results do not account for patient attenuation. 
 
 53
3.4 DISCUSSION 
 
Table 3.5 compares the experimental, empirical and modelling results of the theatre 
shielding arrangement at strategic locations within and around the operating theatre suite 
on level 2 of the PMCC site. The model generally agrees with the measurements within a 
factor of 3 for survey points around the operating suite, which is a reasonable agreement 
in radiation protection terms. However, a significant difference was revealed for both the 
roof above and the floor below (Table 3.4). The empirical calculations consistently over 
estimate the measurements, typically by a multiplication factor ranging from 3 to 7 
(Table 3.5). The Monte Carlo evaluation of each shielding component revealed that the 
mobile shielding, table shielding and lead lined doors reduce dose rate to survey points 
by a factor of 17, 17 and 7, respectively. This compares to a measured attenuation factor 
of 15, 8, and 6 for the mobile shields, under table shielding and lead lined doors, 
respectively (Sephton et al. 1999). 
 
3.4.1 Roof and floor structure 
 
In the case of the roof, both the empirical calculations (Table 3.2) and Monte Carlo 
simulation (Table 3.4) predicted a dose rate greater than measurement by a factor of 5 
and 6, respectively. Results reveal that the absence of shielding had little effect on the 
dose rate simulated at the roof survey position. This validation shows there is no 
measurable scatter contribution from shielding to the roof. This is a clear example of the 
complimentary need for measurement as well as theoretical approaches which have here 
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underestimated the absorption properties of the roofing material. The accuracy of the 
model is highly dependant on how well the construction of the theatre suite and floors 
above and below are known. The calculated dose rates assume a uniform thickness of 
concrete for the roof and floor as described in a survey report of architectural drawings. 
The precise structure was not known. The discrepancy may indicate that the roof and 
floor have structural components not known from the evaluation of architectural 
drawings, for example, the effect of concrete edge pieces on the 192Ir spectrum. 
 
Further simulations revealed that an extra 17 cm thickness of concrete equivalent material 
attenuates the dose to the level consistent with measurement, although it is likely that a 
non-uniform structure is present. It is recommended that a further test of the attenuation 
properties of the roof is to use a mono-energetic source such as 137Cs and to conduct 
direct attenuation measurements. Where unknown structures are likely to be present, 
direct attenuation measurements using a mono-energetic source such as 137Cs could be 
conducted to determine absorption properties for inclusion in modelling. 
 
Results indicate that the 5mm thick steel base of the simulated operating table reduced 
dose by a factor of 1.25. 
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3.4.2 Empirical Calculations 
 
While conservatism is routine in radiation protection practice, unnecessary over-
estimation could result in a costly addition of extra shielding. For the PMCC site, the 
survey points associated with the largest over-estimates of hourly dose rates by empirical 
calculations were the theatre clean-up area outside chain 2 (Figure 3.1) and CSSD (Figure 
3.3a). Both of these survey points are in direct line of sight of the source, with the theatre 
door and single mobile shield in the pathway, and represent the largest uncertainties and 
potentially the most costly. This could also have implications for ease of use of mobile 
shielding effecting workflow, if for example, the mobile shielding is too heavy in design 
positioning might require more than one person to operate or require a mechanical 
approach. 
 
3.4.3 ICRP 101 recommendation 
 
The annual dose to members of the public cannot be directly measured, it is 
recommended in ICRP 101 (2006) to characterize a representative person, where dose 
can be used for establishing compliance with the regulatory dose constraints and dose 
limits. Dose was measured with the ‘collective dose’ philosophy in mind as pointed out 
in Chapter 2. For experimental measurements, with the exception of the theatre setup 
point at 0.405 mSv/yr, all survey points outside the zero occupancy areas were well 
below the annual dose limit to the public. Monte Carlo simulation verified that in reality 
dose exposure can be halved due to scattering from the patient (Table 3.4, e.g. theatre 
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setup). Therefore, exposure estimates for 60 hours per year workload indicate that no 
additional shielding would be needed to comply with a 0.3 mSv/yr dose constraint. 
 
3.4.4 Validation against Toyola site results 
 
As an additional validation of the Monte Carlo simulation of theatre design, a model was 
constructed of a conventionally structured brachytherapy facility. The model of the 
Toyola site (Glasgow 2006) was designed using published details and simulated dose 
rates were compared with those published. Reasonable agreement was achieved for all 
survey points considered, providing greater confidence for the use of the simulation with 
respect to the PMCC facility evaluation. 
  
 
3.4.5 Survey point 12 
 
A Monte Carlo simulation study was made of a scenario where the shielding was not 
positioned for treatment and the lead-lined doors to the theatre not present. At chain 4 the 
comparison revealed that the scatter component is very significant with an increase in 
exposure of a factor of 50. For future radiation protection evaluations it is recommended 
that measurements at survey point 12 be included due the sensitivity of the location to 
changes in attenuation. 
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3.5 CONCLUSION 
 
This study evaluates the effectiveness of additional shielding added to a novel modular 
shielding system without modification of the previously determined time and distance 
constraints for PMCC staff, other patients and members of the public. The DOSXYZnrc 
user code for the EGSnrc Monte Carlo radiation transport code has been used to model 
exposure pathways to strategic locations used for measurement in and around the 
operating theatre suite. 
 
Monte Carlo modeling has been performed with and without shielding to test a number of 
scenarios. Monte Carlo testing of the shielding components is in agreement with 
measurement except through floor and roof. Modeling allows exposure pathways to 
various areas within a facility to be tested without the need to use a real radioactive 
source. It is also useful for testing the scattering effects of different objects with the 
treatment room, such as the operating table, without the need to physically perform the 
measurement. 
 
Reasonable agreement exists between Monte Carlo and measurement except at the level 
above the theatre and below the treatment room floor. The discrepancy implies there is a 
structural component in the ceiling that has not be identified from architecture drawings. 
Monte Carlo calculations indicate that measured dose was attenuated by an extra 17 cm 
of concrete equivalent material. 
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Monte Carlo is useful for calculation in areas where radiation scatter is significant. 
However, it is recognised that an accurate description of the theatre suite is critical as 
large discrepancies can occur. The usefulness of Monte Carlo simulations is evident 
when exploring a range of possible scenarios e.g. modeling new components within the 
treatment room. 
 
As a result of this work the following recommendations are given: 
 
• An extra measurement point, survey point 12, should be considered as it is very 
sensitive to changes in mobile shielding arrangement; and 
 
• The use of Monte Carlo simulations when planning a new treatment facility may 
allow additional optimisation of design. 
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Chapter 4 
 
 
An Experimental MOSFET Approach to 
Characterize 192Ir HDR Source Anisotropy 
 
 
The anisotropy of dose around a 192Ir HDR source in a water phantom has been measured using 
MOSFETs as relative dosimeters. In addition, modeling using the EGSnrc code has been 
performed to provide a complete dose distribution consistent with the MOSFET measurements. 
Doses around the Nucletron “classic” 192Ir HDR source were measured for a range of radial 
distances from 5 to 30 mm within a 40 x 30 x 30 cm3 water phantom, using a TN-RD-50 
MOSFET dosimetry system with an active area of 0.2 mm by 0.2 mm. For each successive 
measurement a linear stepper capable of movement in intervals of 0.0125 mm re-positioned the 
MOSFET at the required radial distance, while a rotational stepper enabled angular displacement 
of the source at intervals of 0.9°. The source-dosimeter arrangement within the water phantom 
was modeled using the standardized cylindrical geometry of the DOSRZnrc user code. In general, 
the measured relative anisotropy at each radial distance from 5 mm to 30 mm is in good 
agreement with the EGSnrc simulations, benchmark Monte Carlo simulation and TLD 
measurements where they exist. The experimental approach employing a MOSFET detection 
system of small size, high spatial resolution and fast read out capability allowed a practical 
approach to the determination of dose anisotropy around a HDR source. 
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4.1 INTRODUCTION 
 
Ideally, a treatment source would be a point source, but in reality the geometry is more 
complex. In remote afterloading High Dose Rate (HDR) brachytherapy the source is 
normally cylindrical, made of high-Z elements, encapsulated in stainless steel, is not quite 
symmetrical with respect to the source’s transverse axis and has one end welded to a 
stainless steel drive cable. As different source designs vary structurally, the AAPM 
produced its TG-43 protocol (Nath et al. 1995) to calculate absorbed dose to surrounding 
geometric points. The protocol achieves this by utilising values of source-specific 
physical quantities from proven experimental or Monte Carlo methods (Williamson 
2005). In 2004, an extensive review of reference-quality dosimetry datasets for low 
energy brachytherapy sources was published by the AAPM in report TG-43U1 (Rivard et 
al. 2004). However, a similar review for 192Ir photon sources used by HDR afterloading 
units is yet to be released (Li et al. 2007). The issue of reliable comparative data is 
significant as such data is required for clinical quality control and this requires 
appropriate methods and procedures for the acquisition of such datasets by widely 
adopted dosimeters i.e., usually TLDs or diodes (Williamson and Rivard 2005). 
 
Previous studies using TLDs within solid water phantoms have collected anisotropy 
datasets at radial distances from 10 to 100 mm through a range of polar angles (Moerland 
et al. 1992, Muller-Runker and Cho 1994, Anctil et al. 1998, Karaiskos et al. 1998). 
These datasets are generally incomplete at backward angles for distances less than 30 mm 
due to physical difficulties arising from the physical presence of the drive cable, the 
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phantom construction and dosimeter dimensions (Gromoll and Karg 2002). Experiments 
are performed by surrounding the source with dosimeters in well defined positions; 
however the source is driven out of the afterloader to a pre-determined position within a 
catheter. The clearance required for the source in the catheter causes positional and 
orientation uncertainty and the drive cable aligned with the axis of source restricts the 
accessible angles for measurement. Investigators (Baltas et al. 1993, Piermattei et al. 
2002) have reported that introducing the source with a catheter increases positional 
uncertainty since the source’s longitudinal axis is generally not parallel to the catheter’s 
central axis. Piermattei et al. (2002) estimated a positional uncertainty of ± 0.1 mm, 
which introduces to the uncertainty an additional 0.3% at 30 mm increasing to 2% at 5 
mm. An alternate measurement approach by Kirov et al. (1995) in which the source is 
removed from the afterloader, has its cable trimmed to a length of 7.5 mm and fixed 
within a machined cavity of their solid-water slab may better address source position 
accuracy. 
 
Research is continuing with a number of other dosimeters for HDR 192Ir source dosimetry 
including miniature ionization chambers (Mishra et al. 1997, Gromoll and Karg 2002), 
diamond dosimeters (Rustgi 1998, Nakano et al. 2003), scintillation dosimeters (Lambert 
et al. 2007) and polymer gels (Kipouros et al. 2003). So far, despite excellent spatial 
resolution and fast dose readout properties, only a small amount of research has been 
published on the feasibility of utilizing MOSFET dosimeters (Zilio et al. 2006, Larallee 
et al. 2006, Lambert et al. 2007) for 192Ir dosimetry. The energy dependence of the 
MOSFETs due to the increase in the mass attenuation ratio of Si relative to water at low 
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photon energies has now been well investigated (Edwards et al. 1997, Kron et al. 1998, 
Wang et al. 2004, Zilio et al. 2006, Larallee et al. 2006). Recently, Larallee et al (2006) 
found that for 150 kVp (mean energy 70.1 keV) X-rays, 192Ir (mean energy 380 keV) and 
60Co (mean energy 1250 keV) that the calibration factor measured in water was 8.54 ± 
0.19, 3.417 ± 0.083 and 3.124 ± 0.053 mV/cGy, respectively. The small differences in the 
mean energy at each dosimeter angle has a very small effect on calibration factor which is 
neglected in this work. 
 
The aim of this study was to investigate the feasibility of using the MOSFET dosimetry 
system by Thomson & Nielsen (model TN-RD-50) to characterize the anisotropic 
distribution of the Nucletron HDR “classic” 192Ir source. Of particular interest to this 
study was the desire to utilize the high spatial resolution capabilities of the dosimeter at a 
radial distance of 5 mm from the 192Ir source where a region of high dose gradient exists. 
In this near field, a further requirement was to design an experimental source-dosimeter 
geometry that enabled data collection through an angular range greater than 90°. The 
MOSFET results were compared to a model of the experimental arrangement using the 
DOSRZnrc (Rogers et al. 2005) user code for the EGSnrc radiation transport simulation 
code (Kawrakow and Rogers 2003), benchmarked against other Monte Carlo results 
(Williamson and Li 1995) and TLD data (Kirov et al. 1995). 
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4.2 METHODS AND MATERIALS 
 
4.2.1 Measurement formalism 
 
The source anisotropy function, ( )θ,rF , is defined: 
  ( ) ( ) ( ) ( ) ( )θθθθθ ,,,,, 00 rGrDrGrDrF &&=              (4.1) 
 
where r  is the radial distance from the active center of the source; 
θ  is the angle subtended by the dosimeter with respect to the source’s long 
axis; 
 
( )θ,rD&  is the dose rate measured at the point ( )θ,r  and ( )0,θrD&  is the 
normalizing dose rate measured at the point ( )°= 90, 0θr ; and 
 
( )θ,rG  is the geometry factor calculated at the point ( )θ,r  and ( )0,θrG  is 
the geometry factor calculated at the point ( )°= 90, 0θr . 
 
For practical purposes, the TG-43 report recommends relatively simple forms of the 
geometry function, ( )θ,rG , and for line sources is defined as; 
 
( )
θ
βθ
sin
,
lr
rG =                (4.2) 
 
where r  is the radial distance from the active center of the source 
β  is the angle subtended by the active source with respect to the point of 
calculation ( )θ,r ; and 
l  is the active length of the source. 
 
The line sources approximation is graphically represented by Figure 4.1. 
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Figure 4.1 Geometry factor for a source of length 3.5mm using model (4.2) and r = 
0.5, 1.0, 1.5, 2.5, 3.0, and 5.0 cm 
 
4.2.2 MOSFET measurements 
 
At the end of the source’s useful clinical life the Nucletron ‘classic’ 192Ir HDR source 
was chosen for the investigation due to its availability at the Peter MacCallum Cancer 
Centre. To maintain short dose delivery times for patient treatments, the Afterloader’s 
370 GBq 192Ir source is typically replaced when its activity has fallen below 167 GBq. 
For the purpose of safe handling during anisotropy measurement, the source was placed 
in an external safe to decay further to an activity of less than 9 GBq. For these 
measurements the source with the full length drive cable still intact was detached from 
the HDR afterloader. 
 
Setup: The measurement water phantom (Figure 4.2) of dimensions 40 x 30 x 30 cm3 
based on the directly mounted source design described in Williamson et al. (1993), 
utilized motorized micrometer positioning to set radial distances. 
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Figure 4.2 Water phantom and computer controlled position apparatus built ‘in-house’ 
employed for measurement of the source anisotropy. 
 
The perspex phantom walls were more than 100 mm from the source-dosimeter 
arrangement. For these measurements the source holder (Delrin rod shown in Figure 
4.3) was machined to provide a snug fit for a decayed 192Ir source. The precise motorized 
rotation stepper stage to which a HDR 192Ir source was mounted to allow rotation through 
angular steps of 0.9°. For each radial distance investigated, the linear stepper motor 
allowed the dosimeter to be re-positioned in step intervals of 0.0125 mm. Apart from the 
fundamental consideration of precise and reproducible source-dosimeter geometries, 
remote positioning aids in reducing overall experimental time, and minimizes the time 
investigators need be in close proximity to the source.  
 
Rotation stage 
Linear stage 
Source 
mounting jig 
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Figure 4.3 A picture of the source–dosimeter geometry showing the 
dosimeter parked at a radial distance a few millimeters beyond the 1 cm 
reference position visually indicated by the laser beam. 
 
 
 
 
Figure 4.4 A Reader (model TN-RD-10), Bias Supply and MOSFET dosimeter form 
the main components of the Patient Dose Verification system (model TN-RD-50) 
manufactured by Thomson & Nielson Electronics. 
192
Ir Source 
MOSFET dosimeter 
Laser beam 
1.0cm from axis 
of rotation 
Delrin rod 
Bias supply 
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A serial port of the control module computer was connected directly to the serial 
input/output device of the MOSFET reader (Figure 4.4). 
 
The interface allowed the MOSFET voltage change over a preset time interval to be read 
remotely. Using the same software interface, the remote control module also controlled 
the stepper motors (Figure 4.5). Motion control of the source holder includes rotation 
speed, direction and degree of the angular step interval. Controls for the dosimeter stage 
include advancement and retraction relative to the source, speed and linear step interval. 
 
 
Figure 4.5 The user interface of the remote positioning and detection control software 
provides access to all functions in the one window. 
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Source position calibration: The active volume of the MOSFET (model TN-RD-21) has 
an area of approximately 0.04 mm2 and is less than 1 µm thick. This structure is covered 
by epoxy featuring a curved side and a flat side. The semiconductor chip is visible from 
the flat side of the epoxy and is approximately 1 mm from the outer edge. During the 
experiment, the MOSFET’s flat side faced toward the source with the centre of the active 
detection structure aligned to the long axis of the source. The alignment of the source-
dosimeter geometry is a two step process. 
 
Step 1: A 10.0 mm cylindrical pointer is initially inserted in place of the source in the 
Delrin rod (see Figure 4.3). The dosimeter is then driven towards the pointer until they 
meet. To calibrate the linear stage, the radial distance from the centre of the rotating 
Delrin source holder to the surface of the detection volume is calculated and a reference 
position is set. By way of a physical marker, a 1 mm diameter laser beam (shown in 
Figure 4.3) is set to intersect the reference position. The uncertainty in radial and vertical 
alignment is estimated to be 0.2 mm. 
 
Step 2: The MOSFET is driven away from the source location, the pointer is removed 
and the phantom filled with water. The HDR source is inserted into the source cavity with 
long handled tweezers and its position adjusted until the capsule tip is aligned with the 
edge of the cylindrical holder, at which point, the centre of radioactivity (according to the 
source dimensions supplied) will coincide with the axis of rotation. In the near field the 
measured dose rate is sensitive to a 0.2 mm change in source positioning about the axis of 
rotation. 
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Measurement: As a HDR 192Ir source is not symmetrical about the lateral axis due to the 
drive cable and its attachment, it is necessary to investigate the anisotropy function both 
at forward and backward angles around the source (Figure 4.6). The specified angle, θ, is 
expressed relative to the longitudinal axis of the source, with 0° indicating the tip and 
180° being at the cable end of the source centre. The measured dose was averaged from 
measurements recorded on both sides of the source. The difference between 
measurements taken at angle θ and those taken at 360°- θ was typically less than 1%. To 
enable adequate reproducibility, individual measurement times ranged from 
approximately 60 to 190s depending on the source strength at the time of measurement 
and the radial distance. The change in dosimeter threshold voltage for individual 
measurements averaged 65 mV (ranging from 23 to 152 mV), the overall change in 
threshold voltage for each dataset averaged 3275 mV (ranging from 1163 to 7423 mV). 
180 0
90
270
 
 
Figure 4.6. The source-dosimeter geometry of the MOSFET experiments through 360°. 
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At small radial distances, the physical dimensions of the solid source, dosimeter and 
mounting apparatus dictate the range of anisotropy measurement points that are attainable 
close to the long axis. Although it is possible to drive a dosimeter within a few 
millimetres of the source at the angular position of 90°, close measurements are inhibited 
by the drive cable near 180°. In the present study, the flexibility of the drive cable 
allowed for maximum measurement angles of 135°, 170°, and 176° for the radial 
distances of 5, 10 and 15 mm respectively. Measurements along the longitudinal source 
axis at 180° were possible for the radial distances of 25 and 30 mm since the effective 
length of drive cable between the source and dosimeter was approximately 15 mm. 
 
The drive cable welded to one end of the source is the main contributor to asymmetry in 
the anisotropy distribution. Conspicuous unexpected asymmetry indicated a potential 
geometrical error or a change in dosimeter sensitivity (Larallee et al. 2006). This was 
addressed by setting the source-dosimeter geometry afresh, or replacing the MOSFET 
respectively. Constancy of dosimeter response was verified for each dataset by 
comparing measurements at the maximum dose rate positions (i.e. at 90° and 270°) at the 
beginning and end of each set of measurements. 
 
4.2.2.1 The MOSFET detection system 
 
The MOSFET radiation sensor is a microelectronic device consisting of radiation 
sensitive insulating silicon dioxide layer sandwiched between a p-type silicon 
semiconductor substrate and a metal gate. The basic physical operation of MOSFET 
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dosimetry, shown in Figure 4.7, can be explained as follows. Before irradiation a 
negative bias is applied to the gate, holes within the doped silicon substrate are attracted 
toward it, unable to pass into the SiO2 insulator positive charge accumulates at the 
Si/SiO2 interface (Soubra et al. 1994). The sufficient buildup of positive charge enables 
current to pass through the silicon substrate from the source to the drain terminal. The 
gate voltage necessary to allow formation of this p-channel and subsequent conduction 
through the MOSFET is known as the threshold voltage. 
 
Figure 4.7 Cross-section of a MOSFET showing the SiO2 layer, the Si substrate, and 
p-channel open between the source and the drain (Soubra et al. 1994). 
 
When the MOSFET is exposed to incident ionizing radiation electron-hole pairs are 
generated within the insulating layer. Electrons, whose mobility in SiO2 at room 
temperature is approximately 4 orders of magnitude greater than holes, quickly move out 
of the SiO2 layer and toward the positively biased contacts via the p-channel (Soubra et 
al. 1994). Depending on the field strength due to the applied bias as well as the energy 
and kind of incident particle some fraction of electrons and holes will recombine. 
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The holes that escape initial recombination are relatively immobile compared with the 
electrons they undergo stochastic hopping through the oxide in response to the applied 
electric field. When the holes are close (about 5nm) to the Si / SiO2 interface, some of 
them are captured in long-term trapping sites. 
 
Figure 4.8 depicts the negative shift in threshold voltage, ∆ VTH, after the MOSFET has 
been irradiated. Since radiation has produced additional positive charge in the oxide, the 
gate voltage must be increased to a more negative value to maintain the same source-
drain current. The shift in gate voltage required to produce a specified source-drain 
current, is proportional to the change in the quantity of trapped charges and in turn is 
proportional to the dose delivered. 
 
Figure 4.8 The effect of radiation on Threshold voltage quantified by the Threshold 
voltage shift ∆ VTH (V before exposure –V after) (Soubra et al. 1994). 
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Each T&N sensor consists of two MOSFET devices, mounted together, operating at 
different bias voltages. The measured voltage is the difference in response between the 
two MOSFET devices comprising each dosimeter. A single MOSFET is sensitive to 
temperature and also exhibits a decreasing response as a function of accumulated 
radiation dose. These effects are nearly eliminated by measuring the response difference 
between a matched pair of MOSFET devices formed on the same silicon chip and 
operated at two different negative gate biases (Soubra et al. 1994). 
 
4.2.2.2 Experimental Uncertainty Analysis 
The detailed approach to uncertainty in experimental measurement includes an analysis 
of statistical (Type A) and systematic (Type B) uncertainties. The uncertainty values in 
the MOSFET experimental measurements of relative anisotropy functions are presented 
in Table 4.1 with a confidence level of 68%.  
 
Table 4.1 MOSFET experimental uncertainty.      
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Distance (mm) 5 10 15 25 30 
 
Repetitive measurement 
 
5.6% 
 
4.8% 
 
4.1% 
 
3.0% 
 
3.3% 
      
Source uncertainty: 
     Rotation  
 
 
1.0% 
 
1.0% 
 
1.0% 
 
1.0% 
 
1.0% 
     Longitudinal  
 
4.0% 2.0% 1.3% 0.8% 0.7% 
Dosimeter uncertainty:      
     Positional  
 
5.7% 2.8% 1.9% 1.1% 0.9% 
      
Total Uncertainty 9.0% 5.6% 5.1% 3.3% 3.6% 
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The Type A uncertainty of most significance is associated with the statistical variation in 
repetitive measurement of MOSFET threshold voltage. The Type B uncertainty of 
greatest significance is positional uncertainty associated with the geometry of the source-
dosimeter arrangement. As the uncertainty in positioning is 0.2 mm, its effect increases 
with decreasing radial distance. Since the transverse uncertainty is accounted for in the 
process of summing measurements taken on opposite sides of the source, we need only 
consider the 0.2 mm uncertainty in the vertical and longitudinal directions. The overall 
uncertainty due to longitudinal and vertical positioning has been calculated for each 
radial distance and listed in table 4.1. The uncertainty in the source’s central axis of 
activity relative to the axis of rotation is estimated to be 0.2 mm. As the rotation of the 
source was known to less than 1° and the steepest section of Williamson and Li (1995) 
anisotropy functions vary in the order of 1% per degree of rotation, a 1% uncertainty in 
source rotation has been included. 
 
4.2.3 Monte Carlo simulation of dose to silicon 
 
EGSnrc simulations (Kawrakow et al. 2003) of the experimental MOSFET 
measurements performed were part of the verification analysis. The EGS Monte Carlo 
code is well benchmarked and recommended by the AAPM (Rivard et al. 2004) for 
characterizing brachytherapy sources. It has been employed by a number of researchers 
examining 192Ir HDR sources for a range of tasks, including obtaining a calibration 
coefficient NK (Mainegra-Hing and Rogers 2006) and characteristic dosimetric 
parameters (Russel and Ahnesjo 1996, Wang and Sloboda 1996, Piermattei et al. 2002). 
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The cylindrical geometry user code, DOSRZnrc (Rogers et al. 2005), was employed to 
simulate the experimental setup primarily because of the cylindrical symmetrical of the 
192Ir source under investigation. The dosimeter was represented at each position by a 
silicon annulus located at the perpendicular distance r from the long axis and axial 
coordinate z. To improve efficiency and reduce simulation times the volume of the 
annulus is much larger than the active volume of the MOSFET dosimeter and had a 
perpendicular thickness, ∆r, of 0.1 mm and axial thickness, ∆z, of 0.1 mm. At least 10 cm 
of water was maintained around the dosimeter annulus in each simulation. 
 
In this study, the source was modeled using the standard routine for uniform isotropically 
radiating disk source. The simulation utilized the 192Ir spectrum, Ir192_bare_1993 
(Duchemin and Coursol 1993), producing an initial spectrum with an average energy of 
345 keV (Rogers et al. 2005, Borg and Rogers 1999), emitted from the cylindrical 
iridium (density 22.42 gcm-2) source region within the encapsulation. The simulation 
modeled the source encapsulation and drive cable with both consisting of stainless steel, 
AISI 316L (Density 8.02 gcm-2, composition Fe 68%, Cr 17%, Ni 12%, Mn 2%, and Si 
1%). The hemispherical source tip was approximated using cylindrical slices 0.04 mm 
and 0.08 mm thick in radial increments ranging from 0.001 mm to 0.05 mm. The main 
cylindrical body of the encapsulation has a radius 0.55 mm. The modeled geometry is 
illustrated in Figure 4.9. The photons interacting within the simulated dosimeter allows 
simulation of dose averaged over the volume of the dosimeter annulus. The dose rate at 
the dosimeter was predicted by tracking at least 109 photon histories to the simulated 
dosimeter. The simulated photon interactions included photoelectric absorption, bound 
Compton scattering, pair production, Rayleigh scattering, and atomic relaxation. 
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Figure 4.9. The source and dosimeter arrangement within the water phantom 
modeled using standardized cylindrical geometry of the DOSRZnrc user code 
(Rogers et al. 2005) for the EGSnrc Monte Carlo radiation transport simulation 
code(Kawrakow and Rogers 2003). The model is shown in the (r, z) co-ordinate 
system used in DOSRZnrc. 
 
4.2.3.1. EGSnrc uncertainties 
The statistical uncertainty in modeled dose rate was less than 1% for all angles, except at 
0° being on the long axis of the source where the geometrical efficiency is lowest. The 
uncertainty was determined from the standard deviation of multiple simulation runs at 
each radial distance. Across all distances the percentage standard error in the normalized 
calculated dose rate reached a maximum value of 3.4% (at 0°) with the average being 
2.7%. Monte Carlo calculations are not explicitly affected by the uncertainty in source 
and dosimeter positioning, dosimeter volume averaging or other dosimeter artifacts. 
However, as pointed out by Williamson et al. (1993) and others the accuracy is highly 
dependant on a detailed source spectrum, accurate interaction cross-sections, and a 
realistic model of the source construction and geometric arrangement under investigation. 
The combined contribution to uncertainty from these effects is estimated at 2%. The total 
uncertainty of the Monte Carlo calculations is 2.2% except at 0° where an average value 
of 3.4% is calculated. 
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4.2.3.2 Monte Carlo simulation of dose to water 
 
In their publication, Williamson and Li (1995) describe anisotropy generated in water 
about the Nucletron ‘classic’ (1991 design) HDR 192Ir source (model No 080950) with a 
Monte Carlo photon-transport code (MCPT). The photon histories were subject to the 
probability of photoelectric absorption (followed by K-shell and/or L-shell characteristic 
X-ray emission), coherent and incoherent scattering, and pair production. The 
composition, location, and dimensions of each geometric region were independently 
specified to provide a realistic model (Figure 4.10). Specifications were based on the 
radiographically verified vendor specifications (Daskalov et al. 1998). 
  
Figure 4.10 The geometry used for modeling of the 192Ir source by MCPT. Material 
composition: core-pure iridium metal (density, ρ=22.42 gcm-3) with uniformly 
distributed radioactive 192Ir throughout the volume; AISI 316L steel capsule (density, 
ρ=8.02 gcm-3). All quoted dimensions are in mm (Daskalov et al. 2000). 
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In each instance the code described the desired stainless steel source capsule containing a 
single iridium cylinder with the 192Ir uniformly distributed. The stainless steel 
components were approximated by the composition of AISI 316L (by weight, 2% Mn, 
1% Si, 17% Cr, 12% Ni, and 68% Fe), which has a density of 8.02 gcm-3. The code input 
data, primary photon spectra and photon interaction cross-sections were those of 
Glasgow and Dillman (1979) and the DLC-99 library (Russin et al., 1983), respectively. 
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4.4 RESULTS 
 
MOSFET normalized dose profiles for the Nucletron “classic” source as functions of 
radii and angle are presented in Figure 4.11. 
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Figure 4.11. MOSFET dose profiles at radial distances from 5 - 30 mm. 
 
The derived experimental and modeled anisotropy function datasets at radial distances 
from 5 mm – 30 mm are presented in Table 4.2. The values at each radius are normalized 
to the dosimeter response at 90° and corrected for 1/r2 dependence using the line source 
Geometry function as defined in the TG-43 formalism (Nath et al. 1995). The required 
Geometry function values were determined for a line source length of 3.5 mm. 
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Table 4.2 MOSFET anisotropy function values for the Nucletron ‘classic’ HDR 192Ir 
Source. 
 
 Radial distance from the active source centre 
Angle* 5 mm 10 mm 15 mm 25 mm 30 mm 
(degrees) MOSFET EGSnrc MOSFET EGSnrc MOSFET EGSnrc MOSFET EGSnrc MOSFET EGSnrc 
0 0.64 0.69 0.72 0.61 0.69 0.65 0.70 0.66 0.72 0.73 
10 0.71 0.72  0.69       
14 0.74          
15  0.75 0.83 0.76 0.78 0.79 0.81 0.78 0.82 0.80 
25 0.85          
30   0.91 0.89 0.90 0.90 0.90  0.91  
45 0.93 0.95 0.96 0.97 0.96 0.96 0.96 0.94 0.96 0.96 
60 1.00 0.97 0.99 0.97 0.98 0.97 0.99 0.97 0.98 0.97 
75 1.01    0.98  0.99  1.00  
76   0.99        
90 1 1 1 1 1 
105 1.02  0.99  0.99  1.00  1.00  
120 0.98 0. 96  0.97 0.96 0.96 0.96 0.97 0.96 0.98 
121   0.98        
135 0.95 0.95 0.95 0.95 0.96 0.95 0.93 0.95 0.96 0.96 
150   0.87 0.89 0.91 0.90 0.89  0.89  
165   0.79 0.74 0.77 0.75 0.78 0.69 0.79 0.79 
170   0.73 0.65       
176     0.62      
180       0.62  0.60  
*Angles relative to the source tip. 
 
4.5 DISCUSSION 
 
Figures 12a,b,c,d,e compare the experimental and modeling results of this study with 
previous modeling (Williamson and Li 1995) and experiment (Kirov et al. 1995) at 5, 10, 
15, 25 and 30 mm, respectively. The experimental results of the current study agree with 
modeling results within estimate uncertainties. In fact, generally the results lie with one 
standard deviation which is suggestive that the assessed uncertainties are conservative. 
Similarly, comparisons between the results and the previous benchmark Monte Carlo 
results of Williamson and Li (1995) as well as the experimental TLD data of Kirov et al. 
(1995) agree except at 0° where there are some differences beyond one standard 
deviation. These differences are not considered significant by the authors as the current 
results neither lie consistently higher or lower than previous results. 
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Figure 4.12(a) Anisotropy function at 5 mm for the Nucletron HDR ‘classic’ 192Ir 
Source, MOSFETs, EGSnrc and Williamson and Li (1995). 
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Figure 4.12(b) Anisotropy function at 10 mm for the Nucletron HDR ‘classic’ 192Ir 
Source, MOSFETs, EGSnrc and Williamson and Li (1995). 
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Figure 4.12(c) Anisotropy function at 15 mm for the Nucletron HDR ‘classic’ 192Ir 
Source, MOSFETs, EGSnrc, Kirov et al. (1995) and Williamson and Li (1995). 
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Figure 4.12(d) Anisotropy function at 25 mm for the Nucletron HDR ‘classic’ 192Ir 
Source, MOSFETs, EGSnrc and Williamson and Li (1995). 
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Figure 4.12(e) Anisotropy function at 15 mm for the Nucletron HDR ‘classic’ 192Ir 
Source, MOSFETs, EGSnrc, Kirov et al. (1995) and Williamson and Li (1995). 
 
The difference at 0° between measurement and Monte Carlo method is unlikely to be 
explained due to the dosimeter’s spatial resolution. Another possibility is an increase in 
MOSFET response due to a change in energy spectrum (Larallee et al. 2006, Zilio et al. 
2006) as a result of more photoelectron interactions in the silicon (Wang et al. 2004). For 
example, at 30 mm Zilio et al. (2006) found that the mean energy is reduced to 269 keV, 
it has been shown with Monte Carlo calculation (Karaiskos et al. 1998) that the average 
spectral energy decreases further towards the longitudinal source axis. Results from 
Monte Carlo modeling in the current study (see Appendix A for details) agree with the 
work of Zilio et al. (2006) for the average photon energy at 30 mm for θ = 45° and 90°. 
At θ = 0° the mean energy is 15 keV lower. Due to the slow change in MOSFET 
sensitivity for energies greater than 200 keV (see Figure 4.13) adapted from Edwards et 
al. (1997)) this energy dependence is negligible. 
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Figure 4.13 The energy sensitivity normalized to that produced by 6 MV X-rays of 
two MOSFET, p-type semiconductor diodes (EDP-10 and EDD-5) and two 
LiF:Mg:Ti TLD (one in PVD, one in NescofilmTM) to low-energy quasi-
monoenergetic X-rays, error bars are ± 1 SD (Edwards et al. 1997). 
 
It is likely that the metal electrodes of the MOSFET dosimeter produce a higher 
photoelectric effect contribution to absorption than tissue. However, the overall result of 
this effect is considered negligible.  
 
Intercomparison of anisotropy results at the polar angle of 180° are complicated by the 
presence of the drive cable. In the geometric model of Williamson and Li (1995) the 
braided stainless steel cable consisted of solid stainless steel 3 mm in length. Kirov et al. 
(1995) trimmed the drive cable to a length of 7.5 mm and in the present study with the 
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cable flexing out of the longitudinal axis resulted in an approximate length of 15 mm. 
Baltas et al. (1998) performed Monte Carlo simulations with and without cable and found 
a pronounced influence of the cable on the anisotropy for angles above 160° with a 
maximum reduction in the dose rate of 13%. Whether experimentally measured or 
theoretically simulated the anisotropy value is highly dependant on the amount of drive 
cable between the source capsule and dosimeter, appropriate caution must be exercised 
when comparing results at 180°. 
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4.6 CONCLUSION 
 
We report an experimental approach employing MOSFETs to measure anisotropy 
function datasets for the Nucletron “classic” 192Ir HDR source. Measurements have been 
performed for radial distances from 5 to 30 mm which extends the range of reported 
measurements to 5 mm which have not been previously reported for this source 
construction. 
 
The experimental arrangements were modeled using the EGSnrc Monte Carlo code 
including the MOSFET which is approximated by Si. The measurements and model were 
benchmarked against published Monte Carlo simulations of the dose distribution as well 
as measurements using thermoluminescent dosimeters where they exist. Good agreement 
was found between the four sets of anisotropy results. The anisotropy of dose is not 
significantly different to the anisotropy of dosimeter response supporting the assumption 
that energy response of the MOSFET is unimportant in this application. 
 
The versatility of the MOSFETs proved more than adequate for the relative dosimetric 
measurements. Highly desirable physical properties for both the experiment design and 
uncertainty analysis included small dosimeter size, high spatial resolution and digital 
readout. These properties were essential to clinical determination of the anisotropy data, 
particularly at the experimentally challenging near radial distances which are 
characterized as regions of high dose gradient.  
 
The motorized source-dosimeter arrangement and the efficient collection of data were 
possible in the water phantom over a wide range of polar angles for radial distances down 
to 5 mm. 
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Chapter 5 
 
 
In Vivo Verification of HDR Prostate Brachytherapy: 
Considerations of Investigative Action 
 
This chapter evaluates the dose delivered in the initial fraction of a four-fraction HDR 
brachytherapy boost treatment for a large group of patients with localized prostate cancer. 
The dose delivered to points within the urethra and rectum is experimentally determined 
using TLD in vivo dosimetry. In vivo measurement as a quality control for the treatment 
actually delivered is effective when dose variation from that planned is impossible to 
determine by any other means.  For example, variations due to needle and template 
movement occurring between imaging and treatment. The current study is significant in 
establishing an in vivo investigative protocol for HDR prostate treatments and is the first 
such study to evaluate a large patient group. Other in vivo studies of HDR prostate 
treatments have so far been for small numbers of patients and do not include 
simultaneous rectal measurements. Monte Carlo radiation transport simulation is used to 
study TLD volume-averaging effects and the influence of radiopaque brass spacers 
separating the TLD’s on the measured dose. 
 
Discrepancies between the urethral and rectal measurements and TPS calculations are 
considered with respect to the relative location of the implant and TLD trains. The 
retrospective assessment of a large number of in vivo studies gives a better understanding 
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of the impact of systematic and random uncertainties and can lead to evidence-based 
justification for a routine single fraction TLD in vivo technique for identifying variations 
in treatment delivery. To evaluate the overall usefulness in routine clinical practice, the 
variations associated with TLD in vivo dosimetry are discussed and recommendations for 
investigative action levels are presented. A proposed corrective action level was 
evaluated for 54 patients and revised to include a recommended investigative action 
level. The use of a single in vivo measurement, in preference to an every-fraction 
approach, is part of the optimization of patient benefit relative to additional workload and 
cost and promotes wider use of in vivo dosimetry. 
 
5.1 BACKGROUND AND INTRODUCTION 
 
PMCC was one of first centers to offer high dose rate prostate brachytherapy within 
Australia. Brachytherapy in combination with external beam radiation therapy (EBRT) 
offers a practical means of dose escalation for patients ensuring that dose tolerance of the 
critical, adjacent normal tissues are not exceeded (Duchesne et al. 2002, Martinez et al. 
2002). The brachytherapy boost treatment is designed to deliver a high dose rate to the 
diseased prostate while giving only a relatively small dose to nearby normal tissue. 
 
In vivo dose measurements have been used for a variety of applications, from verifying 
the accuracy of treatment planning algorithms, to ensuring accurate dose delivery to 
individual patients as well as estimating the global accuracy of dose delivery in a 
department (see for example the review by Essers and Mijnheer (1999) and the references 
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therein). However, such dosimetry is currently only applied in a relatively small number 
of institutions (Essers and Mijheer 1999). Esser and Mijheer (1999) attribute this small 
incidence of in vivo dosimetry to the perception that the gain in patient treatment 
accuracy as a result of in vivo dosimetry will be small compared to the additional 
workload and costs involved.  
 
This study is the first to use urethral and rectal in vivo dosimetry as a dose check for HDR 
prostate brachytherapy. The author adapted the approach from in vivo dosimetry studies 
in gynecological brachytherapy (Westby et al. 1986, Kessaris and Nori 1993). The 
suitability of thermoluminescence dosimeters (TLDs) for dosimetry of 192Ir sources used 
in HDR brachytherapy has been demonstrated (Kron 1995, Kirov et al 1995). The TLD 
train designed for this study was primarily developed by K.R. Das together with the TLD 
calibration protocol (Das et al. 2007). Preliminary results were presented at 2nd Joint 
International Meeting ABS/ GEC-ESTRO/ GLAC by Toye et al. (2000b) in poster form 
entitled, ‘Routine confirmation of urethral and rectal doses for prostate high dose rate 
brachytherapy with in vivo measurement’. The method has since been adopted by the 
PMCC research team and applied to an evidence based complications study, the results of 
which have been recently accepted for publication by the ACPSEM journal (Das et al. 
2007). Differences between the results presented in that work and the current study 
reflect the slightly different patient data sets used in the two bodies of work. Although the 
two databases largely overlap, the present study includes a larger number of patients. 
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5.2 IN VIVO DOSIMETRY: TLD AND LOCALIZATION CONSIDERATIONS 
 
As in treatment delivery, in vivo measurement of dose is reliant on our ability to localise 
points of reference within the body and their spatial relationship with respect to each 
other, as well as the source dwell locations within the treatment volume. Over the past 
two decades there have been a number of clinical investigations of the efficacy of in vivo 
dosimetry for independent measurement of dose resulting from HDR 192Ir brachytherapy. 
Many of these investigations have focused on gynecological applications and the 
associated dose to nearby critical healthy organs such as the rectum and bladder 
(Stuecklschweiger et al. 1991, Kapp et al. 1992, Kessaris and Nori 1993). These studies 
reported successful application of TLD in vivo dosimetry, based on orthogonal film 
localization, to compare TPS calculations with in vivo verification measurements. 
 
More recent TLD in vivo dosimetry studies have examined a small number of patients 
within the high dose gradients associated with HDR prostate brachytherapy (Brezovich et 
al. 2000, Anagnostopoulos et al. 2003). These studies have used CT-based imaging for 
reconstructing the implant and in vivo dosimeter geometry. Anagnostopoulos et al. 
(2003) inserted dosimeters into treatment needles and provided noteworthy uncertainty 
analyses, while Brezovich et al. (2000) described a urethral dosimeter technique. 
 
In 2000, Brezovich et al. reported on an in-vivo method for four patients employing TLD 
rods within the urethra for each of the seven treatment fractions. They showed the 
average agreement between measurement and CT-based TPS calculation were within 2 % 
for the maximum urethral dose. The maximum difference between measurement and TPS 
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calculation for individual fraction was 12% with an uncertainty of 6%. It is of interest to 
the current study to evaluate the influence a larger patient group has on the difference 
between measurement and calculation for an individual fraction. To improve TLD 
localization, Brezovich et al. (2000) suggest studies use radiopaque markers, and place 
the dosimeters within the urethra before imaging for treatment planning. The present 
study used a localization method where radiopaque brass spacers separated the 
dosimeters within the TLD train of the urethra and rectum. Brezovich et al. (2000) 
pointed out that a reliable method for Foley catheter fixing would be necessary if the 
catheter is to remain in place from the time of imaging to treatment delivery which 
required transport of the patient between the imaging and treatment facilities. In the 
present study the use of a mobile C-arm (OEC Medical Systems Inc. Series 9600) 
allowed treatment planning to proceed without moving the patient to a radiography 
department. 
 
Anagnostopoulos et al. (2003) reported on a feasibility study for five patients where 14 
TLD rods were placed into a treatment needle inserted into the prostate during HDR 
brachytherapy. The average difference was determined for each of three treatment 
fractions. The maximum mean difference between planned and measured dose within a 
single fraction was 9% with an uncertainty of 3%. Anagnostopoulos et al. (2003) 
assumed at the center of each 6 mm TLD rod was a positional uncertainty of 1.5 mm due 
to the CT slice thickness. Anagnostopoulos et al. estimate a TLD measurement 
uncertainty reaching 6%. Introduced for doses above 15 Gy is a further systematic error 
due to the supralinearity correction factor. A systematic uncertainty of 2 to 3% was 
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estimated for TPS dose calculation due to source strength uncertainty and the application 
of AAPM TG-43 dosimetry protocol. They report negligible positioning error during the 
first treated fraction owing to the short time of 30 min between CT imaging and treatment 
delivery, as needles were sutured into position. However, it is noted that a possible 1-2 
mm needle positioning error in the subsequent fractions, and a possible 1 mm source 
positioning error during all fractions. In the present study, typically 1 hour elapsed 
between imaging and treatment, however there was no risk of needle or implant 
movement due to patient transport as imaging was conducted in the treatment room. 
 
Anagnostopoulos et al. (2003) have investigated the effect of a high dose gradient on a 
TLD of finite spatial resolution at different close radial distances with Monte Carlo 
simulation. A volume averaging correction factor has been determined at a number of 
radial distances from 0.5 to 2.0 cm. They calculated factors for the classic microSelectron 
HDR 192Ir source and TLD rod, 6 mm in length with a 1 mm diameter, lying parallel with 
midpoints aligned. For this simple geometry Anagnostopoulos et al. (2003) determined a 
maximum correction of 9% at 5 mm. In an actual implant the TLD train is surrounded by 
a number of needles in close proximity, where the center of the source dwell position is 
unlikely to be parallel or at the midpoint of each TLD in the same plane. For this more 
realistic case Anagnostopoulos et al. (2003) found that the correction for volume 
averaging increased measured dose on average by less than 1%. 
 
The issue of LiF:Mg,Ti over-response to a softening effect of 192Ir photons with distance 
has been recently discussed in the literature by Duggan et al. 2004 and Baltas et al. 2004. 
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A brief review of the publications cited by Baltas et al. (2004) in their letter to the editor 
is as follows. Meigooni et al. (1988) found up to 8.5% increase in sensitivity going from 
1 to 10 cm from the 192Ir source, however, other investigators (Thomason and Higgins 
1989) did not detect such a change, within a ±4% reading variation, over a distance from 
1 to 12 cm. Thomason and Higgins (1989) commented that the inverse square law will 
completely mask sensitivity changes with distance. More recent investigators have 
published TLD dosimetry results of 192Ir irradiation with (Anctil et al. 1998) and without 
(Karaiskos et al. 1998, Pradhan et al. 2000) over-response corrections. Karaiskos et al. 
reported the over-response as being within 3% at radial distances less than 15 cm from an 
192Ir source. Pradhan et al. (2000) reported that this over-response did not exceed 2.5%, 
and suggested that the TLDs did not need a significant correction factor. 
 
In the present study the TLD over-response is considered negligible due to the small 
distances between the catheters and the proximal source dwell positions which are 
responsible for the largest contribution to measured dose. 
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5.3 MATERIALS AND METHODS 
 
Routine in vivo measurement of urethral doses was implemented during treatment of 
early stage prostate cancer with HDR Brachytherapy at PMCC within the operating 
theatre facility (Chapter 3). Ethics clearance was granted for this work by the PMCC 
Ethics Committee. Patients at the PMCC received 46 Gy external beam radiation therapy 
in 2 Gy fractions, followed two - three weeks later by 20 Gy of HDR brachytherapy in 
four fractions over 30 hours (Duchesne 2002). For prostate HDR brachytherapy, the 
urethra and rectum are organs at risk of radiation damage and likely to become a limiting 
factor for these procedures if the dose is unacceptably high (Martinez et al. 1995, Mate et 
al. 1998). Thus, the treatment aim was to generate plans that delivered a mean peripheral 
dose of 5 Gy, while keeping urethral doses below 6 Gy (120% of that prescribed 
peripherally) and the rectal doses below 3.5 Gy (70% of that prescribed peripherally). 
 
TLD in vivo dosimetry was performed for the initial HDR fraction using LiF:Mg,Ti 
dosimeter rods (1 mm in diameter and 6 mm in length) manufactured by Harshaw 
Chemicals. Loaded into a fine plastic flexible tube, each train typically consisted of eight 
TLDs alternating with 9 brass spacers (10.0 mm in length). The diameter and length of 
plastic tube was approximately 1.5 mm and 45 cm, respectively. One TLD train was 
placed into the central lumen of an 18 French urethral catheter another was placed within 
a catheter and packed against the anterior wall of the rectum. 
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The theatre facility enabled all facets of the treatment and in vivo dosimetry to go ahead 
without transporting the implanted patient for the purposes of imaging or dose delivery. 
Information collected from two imaging modalities, ultrasonography and X-ray 
fluoroscopy (Figure 5.1) was utilised to localise the in vivo TLD’s. Brass spacers acting 
as radiopaque markers under fluoroscopy identified the TLD positions within the urethra. 
Orthogonal films were taken using a diagnostic mobile C-arm (Figure 5.2). The prostate 
position was localized using transrectal ultrasound imaging. 
 
5.3.1 TLD Calibration technique 
 
A batch of 50 LiF:Mg,Ti rods were used in this work and ideally, all rods should give the 
same response when exposed to the same amount of radiation. However, differences in 
their physical properties (e.g. mass and size) make the dose responses different from one 
another. The relative responses were determined by irradiating the batch of rods with 6 
MV photons from a radiotherapy linear accelerator (Varian 600C) using a standard of 0.5 
Gy (Das et al. 2007). Beam flatness across the TLD’s was verified by routine diode array 
dosimetry. Each rod’s response factor was obtained by comparing the individual response 
value with the average response of the entire batch. During irradiation, the rods were kept 
in a well defined geometry by being placed within cavities machined into a perplex slab. 
The rod factors were verified every 3 months with the Harshaw TLD reader (Model 3500 
Manual TLD reader, Bicron Sait-Gobain/Norton industrial ceramics corporation, Solon, 
Ohio). 
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The TLD’s were numbered as a form of individual identification. The TLD factors were 
determined three times and the rods that showed more than a 2% variation were removed. 
Individual TLD rods were read (Harshaw Model 5500 Automatic TLD Reader) within 24 
hours to avoid fading. The measured data has been corrected for supralinearity as per Yu 
and Luxton (1999). 
 
5.3.2 Orthogonal Reconstruction Technique 
 
The reconstruction technique of the present study involved transferring information about 
the patient's prostate obtained from ultrasound imaging, to orthogonal radiographs that 
showed needle and in vivo catheter information. The straight reconstruction method, 
whereby only the point at each end of the catheter is digitised, was used for each needle 
since it has been found to be a quick and reliable method for the localisation of stepping 
source positions (Fung and Zaider 2000). Having identified the required points on both 
films, their rectangular Cartesian coordinates (x, y, z) were input, via a light box 
digitization method, into the TPS. The planning software then transformed the coordinate 
information, performed the dose calculations and was able to display the dose distribution 
in any plan through the implant. 
 
5.3.2.1 Ultrasonographic localisation 
 
The transrectal ultrasound (TRUS) probe was attached to the stepper carriage and 
mounting apparatus for stability before being used to determine the prostate volume. 
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Operated by the attending Physician, the probe was maneuvered within the rectum until 
the best image was found, without undue compression of the posterior prostate. With the 
mounting apparatus fixed in position, the only stepping movement permitted was 
longitudinal, i.e. along the patient’s superior-inferior direction. A series of transverse 
views were taken of the prostate, from the superior base to the inferior apex. The superior 
surface lying at the bladder neck is conventionally known as the prostate’s base, while 
the inferior surface is referred to as its apex. The depth of probe insertion, tracked by in-
house software, was noted for the base, the apex and the scan showing the largest cross-
section of the prostate. The biplane transducer imaged in both axial and longitudinal 
planes, helping visualise proximity of prostate margins, bladder, urethra, and anterior 
rectum during needle insertion. Reference points were obtained in 0.5 – 1.0 cm 
increments along the z-axis and the length measured along the x- and y- axis. On each of 
these slices the prostate, anterior rectum, and urethra, were identified. The TRUS images 
were visually translated to film and all reference points were digitized into the TPS from 
where the appropriate distribution of source dwell times and positions were calculated. 
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5.3.2.2 Orthogonal Radiographic Localisation 
 
Orthogonal projection of an identifiable point using two radiographic films at 90° is a 
useful method to obtain localisation in three-dimensional space. In the present study, after 
implantation of the treatment needles and in vivo TLD catheter, two successive isocentric 
radiographical projections of the implant region were taken in mutually perpendicular 
directions. Ideally, there should be no motion of the patient between the taking of the 
back-to-front (PA) and left-to-right (lateral) projections. These were obtained with the 
help of a portable diagnostic X-ray C-arm (Figure 5.1). 
 
Figure 5.1 X-ray fluoroscopy: the non-isocentric mobile C-arm positioned for PA 
projection just prior to irradiation within the treatment room. 
 
Figure 5.2 displays the typical radiopaque information to be registered on the two 
orthogonal films. The urethra is clearly visualised on a radiograph mapping its way 
through the prostate, along with the implanted treatment needles and bladder balloon.  
 
C-arm 
Film cassette 
holder 
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Figure 5.2 Lateral orthogonal radiograph depicting the prostate implant geometry, 
including needles, in vivo trains bladder balloon, and centre of field cross. 
 
Prostatic geometric information from ultrasound slices is transposed onto both orthogonal 
films. Figure 5.3 displays the same radiopaque information as Figure 5.2 with the 
addition of the transposed ultrasound prostatic information. Five reference planes have 
been marked onto the radiograph to enable reconstruction of the prostate using the TPS 
software. 
 
Implanted needles 
Brass 1 cm 
spacers 
TLD-100 rod 
Bladder 
balloon 
Urethral 
Catheter 
Rectal 
Catheter 
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Figure 5.3 Lateral orthogonal radiograph with prostatic margin outlined from 
information transposed from ultrasound. The base and apex planes are defined as well 
as three mid-gland planes. 
 
On the lateral film (see Figure 5.3), the anterior and posterior edges of the prostate were 
defined. The base plane of the prostate is at the level of points A0 and P0 and the apex 
plane is at the level of points A3.5 and P3.5. On the corresponding PA film (not depicted) 
the left and right edges of the prostate were defined; the base plane is at the level of 
points L0 and R0 and apex plane at the level of the points L3.5 and R3.5. 
 
1 cm interval 
Apex plane 
Base plane 
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5.3.3 In vivo dosimetry 
 
The brass spacers of the in vivo train being radiopaque markers under fluoroscopy 
defined each end of the TLD. This information is then used to localise each TLD with 
respect to the prostate’s base and apex and source positions within the treatment needles. 
The TPS calculations were performed using Nucletron’s Plato BPS (version 13) where 
each point dose was localized to the midpoint of each TLD rod. A typical plot of 
calculated and measured doses along the catheter is shown in Figure 5.4. 
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Figure 5.4 Comparison of in vivo measured and calculated Urethral dose. The 
measured TLD data are represented by the blue diamonds and TPS calculation by the 
red curve. The urethral length (4.5 cm) is indicated along with the corrective action 
level (6.6 Gy). 
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At the commencement of the current study, an HDR prostate publication reporting on 
urethral in vivo dosimetry did not exist. Henceforth, in the absence of comparable in vivo 
data, the following local corrective action level was proposed: if more than 50% of the 
prostatic urethra received a dose greater than 10 % above the 6 Gy urethral tolerance, 
then subsequent fractions would be modified (see Figure 5.4). 
 
5.3.4 TLD dose uncertainties 
 
The total uncertainty due to TLD calibration and dose response, displacement in 
localization due to variations in film orthogonality and digitization, as well as source 
strength is presented Table 5.1 with a confidence level of 68%. The term of greatest 
significance is positional uncertainty associated with the orthogonality of the films taken 
with a non-isocentric C-arm combined with the uncertainty in the physical digitization 
process. The positional uncertainty for the urethral and rectal TLDs has been estimated 
from the standard deviation in percent dose associated with the shift corrections (Figure 
5.8 and 5.9). This considered a reasonable approximation since the urethra is surrounded 
by dwell positions. The difference between the urethral and rectal TLD positional 
uncertainty is a result of the reduction in dose gradient to the rectum. While a number of 
different sources were commissioned over the course of the data collection, an average 
uncertainty in source strength of 3 % is assumed. The uncertainty in the planning systems 
application of the dose algorithm is estimated to be less than 1 % for 192Ir photons. 
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Table 5.1. Experimental TLD uncertainty. 
 
5.4 RESULTS 
 
In the current study, TLD in vivo dosimetry is evaluated for 56 patients whom received 
HDR prostate brachytherapy. On one occasion after reviewing the doses recorded by the 
TLD train, the treatment regime was subsequently altered. Urethral and rectal 
measurements could not be evaluated for all 56 patients due to incomplete data sets or 
where measurements were not performed. Presented in Figures 5.5 and 5.6 is the ranked 
comparison of 54 urethral and 32 rectal measured data sets to TPS calculated results, 
respectively. The average urethral and rectal dose recorded was 6.0 and 2.3 Gy, 
respectively. 
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Figure 5.5 The ranked comparison of the peak dose difference between urethral 
TLD data and TPS calculation of 54 patients. After a shift correction in 26 patients 
the average difference in peak dose is 6 % with a standard deviation of 20%. 
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Figure 5.6 The ranked comparison of the peak dose difference between urethral TLD 
data and TPS calculation of 32 patients. After a shift correction in 8 patients the 
average difference in peak dose is 19 % with a standard deviation of 33%. 
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Comparison of 30 data sets shows that larger percentage differences in urethral doses 
frequently are reflected in the rectal results. However, for two data sets, a larger 
percentage difference in rectal doses is not reflected in the urethra results Figure 5.9. 
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Figure 5.7 The percentage difference in peak urethral dose is compared to the 
percentage difference in peak rectal dose for 30 patients. A positive value 
represents a greater measured dose, while a negative value represents a 
greater TPS calculated dose. 
 
Recommendations by the ABS (Nag et al. 2000) to record doses received according to 
urethral length, imply that urinary complications arise from high dose radiation volumes 
(Butler et al. 2000). Since this may also be important to HDR prostate brachytherapy, 
urethral dose lengths were estimated. From the 54 patients evaluated, 6 data sets received 
more than 120% of prescribed dose to the urethral TLDs. Urethral lengths for doses of 
more than 7 Gy ranged from 1.0 to 4.3 cm. One data set indicated that at least 7 Gy was 
received by more than 50% of the Urethra. 
 
 
 
Points of large rectal 
dose variation not 
reflected in urethral 
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5.4.1 Uncertainties 
Further contributions to localization uncertainties due to variations in source, implant, 
and TLD train positions can occur between the time of treatment planning reconstruction 
and treatment delivery (approximately 1 hour). These localization uncertainties are 
reflected in the significant increased variation presented in Table 5.2. The average 
percentage difference between the urethral measured data and TPS calculation is 6% with 
a standard deviation of 20 %. The average percentage difference between the rectal 
measured data and TPS calculation is 19% with a standard deviation in of 33 %. 
 
Catheter 
location 
Number of 
Patients 
Range of difference 
(%) 
Systematic 
Difference 
(%) 
Standard 
deviation 
(%) 
 
Urethral 
 
54 
 
-34 
 
66 
 
6 
 
20 
 
Rectal 
 
32 
 
-36 
 
105 
 
19 
 
33 
 
*Statistics are given after correction for the shift 
Table 5.2 Comparison percentage differences between measured and TPS calculated 
doses for the urethral and rectal TLD midpoints. 
 
From the 54 urethral data sets evaluated, 25 required correction in order to compare the 
peak doses due to a positional shift between measurement and the TPS calculated dose 
points. For these 25 data sets the percentage difference in dose between measurement and 
calculation ranged from -26% to 56%. It is interesting to note that for data sets that did not 
display position shift, the range of percentage difference in dose between measurement and 
calculations was -34% to 66%. The average corrective shift of the experimental data set 
was 4 mm with a maximum of 8 mm in the direction of the prostatic apex and perineum. 
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When the original values of percentage difference in dose for the 25 data sets are compared 
to the values after the shift correction, the average change is 5% (1 s.d. = 7%), ranging 
from -11% to 21% (Figure 5.8). The estimated uncertainty in the urethral geometric shift 
correction is 1mm which corresponded to an uncertainty in dose of approximately 1%. 
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Figure 5.8 The ranked comparison of change in percentage difference of urethral dose 
between measurement and TPS calculation as a result of the geometric shift 
correction. 
 
In the case of the rectal data sets, 8 required correction for an offset between the curves of 
the two data sets. In Figure 5.9, the change in percentage difference in dose due to the 
geometric shift correction ranged from -6% to 11% with an average magnitude change in 
dose difference of 4% (1 s.d. = 6%). The average magnitude of lateral shift is 6 mm with 
a maximum of 8 mm. However, no significant directional trend is indicated i.e. towards 
the prostate base or apex. The estimated uncertainty in the rectal geometric shift 
correction is 1mm which corresponded to an uncertainty in dose of less than 1%. 
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Figure 5.9 The ranked comparison of change in percentage difference of rectal dose 
between measurement and TPS calculation as a result of the geometric shift 
correction. 
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5.5 DISCUSSION 
 
In the current study the average measured dose to the urethra was 6.0 Gy with a 2.3 Gy 
average dose to the rectum. Figures 5.5 and 5.6 compare the experimental TLD results 
with TPS calculation of dose to the urethra and rectum, respectively. The retrospective 
evaluation indicates that peak urethral TLD dose is on average 6% higher than 
calculation. For the rectal results, the in vivo measurements are on average 19% higher 
than calculation. Data corrected for positional shift had little impact on the overall 
uncertainty of the peak dose comparisons. In the case of the rectal dosimetry, issues of 
catheter stability hampered the accuracy and precision of measurements, due most 
probably to the influence of strong rectal muscles. The results of the current study 
indicate when significantly larger variations exist between the actual dose delivered and 
that planned i.e. gross errors, but may not be suitable as a check for subtle variations in 
dose. 
 
5.5.1 Evaluation of urethral results 
 
In Figure 5.5, ten measurements show that planned and measured doses differ by more 
than 20%. Six of the ten points lie within two standard deviations. For these points, all 
doses were within urethral and rectal tolerances and no problems were associated with 
the patient or equipment setup. For an individual fraction, Brezovich et al. (2000) found a 
maximum dose difference between urethral measurement and TPS calculation of 12 ± 
6%. However, when averaged for all seven fractions, agreement was within 2%. With the 
current technique, a similar averaging effect is likely to occur over the remaining three 
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treatments. Future work is recommended to study inter-fractional variation for current 
practice before moving to a more optimized initial fraction-only protocol. 
 
The presence of a difference in peak dose between measurement and calculation outside 
two standard deviations does not necessarily implicate clinical intervention. In the current 
study, a large dose difference was recorded in two dose profiles, however, this was 
rejected as being clinically significant because the difference was due to one anomalous 
TLD result in each of the measured profiles. In these cases, when all 8 TLD results within 
the dataset are considered the average difference to TPS calculation is in the opposite 
direction. It is recommended for outlying points beyond two standard deviations that 
further in vivo measurements be performed for the remaining fractions. 
 
The decision regarding whether or not data points outside two standard deviations is an 
indicator for corrective action is a clinical decision, and will depend on whether or not the 
associated doses exceed urethral tolerance. Only one data set showed more than 50% of 
the urethra receiving more than 10% of the tolerance dose, having a peak urethral dose of 
10.0 ± 2.0 Gy. However, the rectal dose did not reflect a similar high dose, instead being 
2.1 ± 0.8 Gy which is lower than average. The remaining data point had a peak dose of 
10.0 ± 2.0 Gy. this single fraction urethral dose is comparable to more recent prescribed 
dose regimes to the prostate PTV, for example 11.5 Gy for each of 2 fractions (Vargas et 
al. 2005). It is strongly recommended, particularly in the case of increased dose per 
fraction, that continued in vivo monitoring be adopted for dose variations above urethral 
tolerance parameters. 
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5.5.2 Implant quality 
 
In the current study, twenty five urethral data sets were corrected for an apparent lateral 
shift in peak dose relative to the TPS dose distribution. As a general guide, a change in 
position of peak dose could be dependent on the localization of implanted needle 
positions, source dwell positions and location of the TLD trains. This particular lateral 
shift could be explained by an overall migration of the implant towards the prostatic apex 
and perineum relative to the TLD train, a shift in urethral probe towards the bladder 
relative to the implanted needles, or a variation of dwell position toward the patients 
distal end. As the observed shift of 4 to 8mm far exceeds any likely variation in intended 
source dwell position this possibility for shift is rejected. 
 
A shift in dose measured along the urethral TLD train was not reflected in rectal results 
for all patients. In Figure 5.5, however, the patient data sets that showed the four highest 
urethra differences in dose between measurement and calculation also showed similar 
differences in the rectal in vivo results. A similar trend was seen in the two patient data 
sets with the highest difference in the negative direction in Figure 5.5. These results 
indicate a correlation between shifts in urethral and rectal results for the large differences, 
which suggests that the apparent shift is unlikely to be caused by TLD train movement. 
 
Therefore, it is more likely that the apparent shift is related to a change in the position of 
the implant. The impact of apparent shift on implant quality (Cygler et al. 2006) will 
largely depend on whether the shift relative to the prostate is greater than the dose margin 
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around the prostate volume provided by the PTV. If the prostate boundary is well 
defined, than in vivo dosimetry data may be useful in providing information about dose 
coverage. 
 
5.5.3 Choice of Dosimeter 
 
Cygler et al. (2006) published a recent study evaluating the feasibility of MOSFET in 
vivo dosimetry within the urethra for a small group of prostate patients treated with low 
dose rate 125I seeds. It recommended that a MOSFET array be used to investigate urethral 
doses of the HDR patients. The use of the MOSFET dosimetry will reduce uncertainties 
due to dosimeter spatial resolution, dose response, and labour intensiveness. The small 
size and metallic components of the MOSFET will aid in reducing localization errors. 
Cygler et al (2006) estimate an uncertainty in MOSFET positioning of ± 1 mm. Duggan 
et al. 2004 suggest that dose response estimations can be improved by applying a more 
straight forward correction factor associated with LiF:Mg,Cu,P dosimeters. Although 
MOSFET has higher energy dependence than LiF:Mg,Ti it is unlikely to introduce the 
need for a major correction in 192Ir HDR brachytherapy (See Chapter 4, Section 4.5 and 
Larallee et al. 2006). 
 
5.5.4 Absorption effects of the brass markers 
 
In the present study a potential effect within the high dose gradient of the PTV was a 
dose perturbation due to the presence of brass markers. The presence of high-Z brass 
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markers may change the absorption and scattering characteristic of the photons exiting 
and entering the ends of the TLD rods. By splitting each TLD rod into twelve, 0.5mm 
regions, a Monte Carlo calculation was employed using the EGSnrc system with 
DOSRZnrc user code (Kawrakow and Rogers 2003, Rogers et al. 2005) in a cylindrical 
geometry, to model dose perturbation across each rod. 
 
Findings are presented for two different geometric relationships between the source and 
TLD at 14 mm. One configuration has the source adjacent to the centre of a TLD which 
is abutted on each end by a brass spacer; for the other, the source is adjacent to the center 
of a brass spacer with a TLD at each end. Results indicate that the effect of the brass 
spacers is not significant for two different parallel spatial relationships between the 
source and TLD (see Appendix for details and related Figures). 
 
5.5.5 Imaging approach. 
 
TPS calculations of the dose at TLD positions do not rely on the localization of the 
prostate. When acquiring the orthogonal films, the non-isocentric C-arm (GE OEC 9800) 
used in the current study must be adjusted linearly after rotating from one field to the 
next. Liu et al (2003) have investigated the accuracy of the GE OEC 9800 mobile C-arm 
and report an overall reconstruction uncertainty of 2 mm. Localization is improved with 
CT imaging, Anagnostopoulos et al. (2003) estimate an uncertainty of 1.5 mm at the 
centre of each 6 mm TLD rod. This also compares favourably with the current study 
where an uncertainty of 3 mm is assumed. 
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In the current study, the prostate volume was identified from ultrasound images and 
reconstructed onto orthogonal films so that all facets of the treatment could go ahead in 
the theatre facility. This eliminated the need to transport the implanted patient for the 
purposes of imaging or dose delivery. However, Anagnostopoulos et al. (2003) found 
that for their technique for fixing the template and needles, results indicated negligible 
movement occurred between imaging the treatment delivery at the first fraction. It is 
recommended that CT-based planning be used for future studies and this is now adopted 
in many centres. 
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5.7 CONCLUSION 
 
An in vivo dosimetry technique employing TLDs to experimentally measure doses 
delivered to the urethra and rectum during HDR prostate brachytherapy is reported. 
Urethral and rectal in vivo measurements have been performed in the initial of four 
fractions for a large patient group. Corrective action [criterion: more than 50% of the 
prostatic urethra received a dose 10% beyond the urethral tolerance] occurred for one 
patient. The in vivo measurements added only a few minutes to the total procedural time 
and served as a confidence check of dose actually delivered. 
 
The measured data was compared to the TPS calculated dose points. Good agreement in 
the general curve-shape of the datasets was found for both the urethral and rectal results. 
For urethral length determinations the use of MRI will reduce localization uncertainties 
of the prostatic boundary due to better image clarity. Nearly 50% of the measured data 
sets indicated a 4 mm shift in the measured dose relative to TPS towards the prostatic 
apex. The standard deviation of difference between measurement and TPS calculation is 
significantly higher for the rectal measurements indicating that the location of the rectal 
TLD train was less clearly defined. 
 
EGSnrc Monte Carlo simulation of the in vivo dosimeter train containing an alternating 
TLD and brass spacer configuration revealed that the brass spaces had negligible impact 
on TLD dose absorption. 
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As a result of this work the following recommendations are made: 
• That a study utilizing CT-based planning be undertaken with a view to reducing 
localization uncertainties to 1.5 mm; 
• That investigative action be performed for all urethral peak results that fall outside 
one standard deviation of difference between measurement and TPS calculation; 
• That further in vivo measurements be performed for the remaining fractions when 
urethral peak results fall beyond two standard deviations of difference between 
measurement and TPS calculation; 
• That continued in vivo monitoring be adopted for dose variations that exceed 
urethral tolerance, particularly when dose is delivered in less than four fractions; 
• That improvement to the rectal catheter fixation be implemented for future 
studies; and 
• That when starting a new technique in vivo dosimetry should be used initially for 
all fractions to establish the average variation of the results for the total treatment. 
This information will assist in setting the level of investigative action before 
adopting a routine initial fraction protocol. 
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Chapter 6 
 
 
Conclusion 
 
6.1 GENERAL 
 
At the commencement of this thesis three unique projects were chosen for investigation, 
all within the clinical setting of the operating theatre environment of the PMCC. Each of 
the three Research Questions asked was aimed at a different level within the HDR 
brachytherapy treatment process. The first question relates to radiation protection within 
and surrounding the HDR facility which must be adequately optimized for both staff and 
the general public. With MOSFET dosimeters, the second project evaluates dose 
anisotropy characterization of the 192Ir source used by the Nucletron HDR afterloader. At 
the level of the patient, the third question evaluates the dose delivered to the prostate 
using TLD in vivo dosimetry. 
 
EGSnrc Monte Carlo radiation transport code was used in the evaluation of the 
experimental results. The modeling was useful for both the small and large range photon 
range problems considered by the current thesis, being used extensively to verify facility 
shielding and source anisotropy experiments. A number of recommendations have arisen 
from this work that may have application in HDR facilities elsewhere. 
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6.1.1 Optimization of modular shielding for radiation protection 
 
For a new or existing HDR facility, optimization of the shielding design is critical since 
the 192Ir source with nominal activity of 370 GBq has the potential to contribute 
significant radiation doses to the brachytherapy team and other theatre staff who may 
spend time within nearby rooms. Modeling allows exposure pathways to various areas 
within a facility to be tested without the need to use real sources. This is also true for 
empirical calculations, however, conservative results are routine in radiation protection 
practice and over-estimation could result in a costly addition of extra shielding. The 
usefulness of Monte Carlo simulations is evident when exploring a range of possible 
scenarios e.g. modeling new components within the treatment room. In the current study 
reasonable agreement exists between Monte Carlo and Survey Area measurements except 
at the level above the theatre and below the treatment room floor. 
 
A potential problem with Monte Carlo calculations is that the accuracy of the simulation 
relies on the knowledge of the structure of the HDR facility. A discrepancy between 
measurement and simulation may indicate that the structural components are not 
precisely described by the architectural drawings. Where discrepancies exist a direct 
attenuation measurement using a mono-energetic source such as 137Cs could be 
conducted to determine absorption properties for inclusion in modelling. 
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6.1.2 MOSFET anisotropy measurements 
 
The anisotropy function is defined by the TG-43 formalism, and that data is used by TPS 
algorithms for calculating patient treatment doses. Independent MOSFET measurements 
were carried out to determine the anisotropic characterisation of the stepping source 
utilized by the HDR afterloader. Measurements performed for radial distances from 5 to 
30 mm, extend the range of measurements to 5 mm which has not been previously 
reported for this source construction. The desirable properties of MOSFET dosimeters 
include their small size, high spatial resolution and direct digital readout. 
 
Anisotropy measurements near to the HDR source at angles very close to 180° are 
restricted due to the physical presence of the drive cable. Anisotropy values at these 
backwards angles have little importance when the source is within a straight catheter or 
needle. However, anisotropy does become important when the drive cable is flexed 
allowing tissues to receive dose at 180°. Whether measured experimentally or 
theoretically simulated, the anisotropy function is highly dependant on the amount of 
drive cable between the source capsule and dosimeter. As there is yet to be specific 
guidance published on determining anisotropy measurements at 180°, appropriate caution 
must be exercised when comparing results of different publications near this angle. 
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6.1.3 In vivo dosimetry 
 
In the application of any brachytherapy technique there exists potential for radiation 
injury to the patient’s nearby normal tissue structures. The combination of a new 
treatment technique, short treatment times, pressure on personnel, and complexity of the 
afterloading unit and TPS creates potential opportunities for treatment errors. At the 
patient level, in vivo dosimetry measurements provided confidence information for the 
global process including the implantation reconstruction used for localisation and the 
method of dose delivery. After review of the 54 TLD measured urethral profiles, the 
treatment regime was subsequently altered in only one case. Corrective action [criterion: 
more than 50% of the prostatic urethra received a dose 10% beyond the urethral 
tolerance] was applied for one patient. The in vivo measurements added only a few 
minutes to the total procedural time. The level for investigative action is considered from 
the analyses of dose differences between measured data and TPS calculations. It is 
recommended for the dose regime of the current study that investigation be invoked when 
the comparison between measured data and TPS calculation differs by more than one 
standard deviation. 
 
The success of urethral and rectal in vivo dosimetry is strongly dependant on the fixation 
of implant and dosimeters. Their positions may be extremely well localized, however if 
movement occurs between imaging and treatment delivery large differences between 
measurement and calculations are likely. If the implant has moved relative to the PTV, 
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than implant quality may change. If the prostate boundary is well defined, then in vivo 
dosimetry data may be useful in providing information about dose coverage. A further 
complicating factor is the high doses encountered within the implant PTV. Significant 
corrections due to the over-response of LiF:Mg,Ti must be made, for example, a 
correction factor in excess of 15 % is required for absorbed doses of 10 Gy or more. 
 
6.2 RECOMMENDATIONS AND FUTURE APPLICATIONS 
 
6.2.1 Optimization of modular shielding for radiation protection 
 
The Monte Carlo simulation is an extremely useful tool for future studies where there 
may be used to fill gaps in the measurable data. Where complex scatter contributions are 
significant and real measurement with a high activity source are impractical Monte Carlo 
simulation is a natural choice with obvious advantages. Future studies using more 
realistic Monte Carlo calculations, in contrast to conservative dose upper bounds arrived 
at using a radiation protection approach, can result in measurable cost reductions. 
 
 
6.2.2 MOSFET anisotropy measurements 
 
To build-on existing experimental anisotropy consensus data, the current study presented 
measured data, along with Monte Carlo verification, of dose anisotropy for the Nucletron 
‘classic’ HDR 192Ir source. The employment of a purpose built water phantom and a 
commercial MOSFET detection system enabled data to be collected at close radial 
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distances. It is recommended that an experimental system similar to the one used in the 
current study be employed to obtain consensus datasets for other high-energy photon-
emitting sources. 
 
At the time of writing this thesis the AAPM have yet to update their TG-43 protocol to 
provide consensus data for high-energy photon-emitting sources such as those made with 
192Ir. For future experimental characterization of HDR source anisotropy, it would be 
useful to develop a standard protocol for dose estimation near the drive cable of the 
source. 
 
6.2.3 In vivo dosimetry 
 
It is highly recommended that in vivo dosimetry be introduced as new treatment 
techniques are implemented into brachytherapy programs. When there is an absence of 
local experience for a specific brachytherapy technique, performing in vivo 
measurements on the first treated patients yields valuable information about the dose 
variations associated with new treatment methodology in daily practice. 
 
The future study of uncertainties associated with an in vivo dosimetry technique should 
include the application of Monte Carlo simulation for interpretation of experimental 
phantom data. This would address the issue of implant shift when investigating the 
reproducibility of in vivo measurements. To reduce uncertainty due to localization, CT 
imaging should be adopted as is usual in modern clinical settings. 
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For future studies, particularly in the case of a new treatment technique or dose regime, in 
vivo dosimetry can be used initially for all fractions to establish the average variation of 
the results for the total treatment. This information will assist in setting the level of 
investigative action before optimizing the in vivo dosimetry to a routine initial fraction 
protocol. 
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APPENDIX A 
 
Monte Carlo Simulation of a TLD Train Element 
Including Brass Spacers 
 
Monte Carlo simulations were performed to investigate the influence of the brass spacers 
on the dose recorded by the TLD’s. Volume averaging masks the extent to which 
scattering in the brass adjacent to the ends of each dosimeter effects the average dose 
recorded. EGSnrc (Kawrakow and Rogers 2003) and the cylindrical geometry user code, 
DOSRZnrc (Rogers et al. 2005), were employed to simulate an element of the TLD train 
in the urethral catheter adjacent to an 192Ir HDR source inside a stainless steel treatment 
needle. Two configurations were modeled representing different spatial relationships 
between the source and a TLD: (i) the source is adjacent to the centre of a TLD which is 
flanked on both ends by brass spacers; and (ii) the source is adjacent to the centre of a 
brace spacer with a TLD at each end. The two configurations are shown in Figure A-1. 
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Figure A-1  The two configurations modeled representing different spatial 
relationships between the HDR brachytherapy source and a TLD: (i) the source is 
adjacent to the centre of a TLD which is flanked on both ends by brass spacers; and 
(ii) the source is adjacent to the centre of a brace spacer with a TLD at each end. 
 
In each case, the TLD’s and brass spacers are surrounded by a plastic tube inside the 
central lumen of the water-filled catheter. The cylindrical symmetry of the TLD’s and 
brass spacers in the catheter is mapped to a cylindrical geometry in the DOSRZnrc model 
with the central axis of the TLD train coincident with the axis of symmetry in the model. 
The source is modeled as an iridium annulus surrounding the TLD train for increased 
calculation efficiency. The 192Ir source is modeled inside a thin walled stainless steel 
annulus representative of the brachytherapy treatment needle, and the drive cable is 
included. The source and TLD train are separated by a centre-to-centre distance of 14 
mm. The surrounding tissue is modeled as water. To provide spatial resolution, the 6 mm 
TLD is modeled as twelve 0.5 mm segments. The geometry is depicted in Figure A-2. 
 
(i) (ii) 
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Figure A-2  The geometric representations of two configurations modeled. In each 
case, the TLD rods are defined in twelve 0.5 mm segments. 
 
The relative dose rate in each segment for model (i) is shown in Figure A-3 for cases with 
and without the presence of the brass spacers flanking the TLD. Note that the horizontal 
axis represents dose scoring zones. Zones 3-15 correspond to the TLD segments. Zones 2 
and 16 represent the region occupied by the brass spacer. Figure A-4 shows the results for 
model (ii). The brass spacer at one end of the TLD rod is included. 
 
The results show in each case that the influence of scatter contributions from the adjacent 
brass spacers has negligible influence on the volume-averaged dose recorded by the 
dosimeter. 
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Figure A-3  The relative dose rate in each segment for model (i) for cases with and 
without the presence of the brass spacers flanking the TLD. Note that the horizontal 
axis represents dose scoring zones. Zones 3-15 correspond to the TLD segments. 
Zones 2 and 16 represent the region occupied by the brass spacer. 
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Figure A-4  The relative dose rate in each segment for model (ii) for cases with and 
without the presence of the brass spacers flanking the TLD. Note that the horizontal 
axis represents dose scoring zones. Zones 2-13 correspond to the TLD segments. 
Zones 14-16 represent the region occupied by the brass spacer. 
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Monte Carlo Simulation of Photon Fluence Energy 
Spectra at MOSFET  
 
at 30 mm  
Average 
Photon energy   
  (MeV)   
region 3 
detector at 0 degrees (small 
voxel) 0.2582 +- 4.40% 
region 33 
detector at ~0 degrees (larger 
voxel) 0.2535 +- 1.60% 
region 
367 detector at 45 degrees  0.2711 +- 0.20% 
region 
499 detector at 90 degrees  0.2699 +- 0.10% 
     
     
     
at 5 mm  
Average 
Photon energy   
  (MeV)   
region 3 detector at 0 degrees (small 0.3544 +/- 0.20% 
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voxel) 
region 33 
detector at ~0 degrees (larger 
voxel) 0.3543 +- 0.10% 
region 
367 detector at 45 degrees  0.3434 +- 0.00% 
region 
499 detector at 90 degrees  0.3389 +- 0.00% 
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